NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

National Collaborating Centre for Mental Health (UK). Depression: The Treatment and Management of Depression in Adults (Updated Edition). Leicester (UK): British Psychological Society; 2010. (NICE Clinical Guidelines, No. 90.)

Cover of Depression

Depression: The Treatment and Management of Depression in Adults (Updated Edition).

Show details

16 REFERENCES

    Please note that due to reasons of space, references to studies reviewed in clinical evidence reviews are in Appendix 17.232

  • Abas M. Depression and anxiety among older Caribbean people in the UK: screening, unmet need and the provision of appropriate services. International Journal of Geriatric Psychiatry. 1996;11:377–382.
  • Abas MA, Phillips C, Carter J, et al. Culturally sensitive validation of screening questionnaires for depression in older African–Caribbean people living in south London. British Journal of Psychiatry. 1998;173:249–254. [PubMed: 9926102]
  • Abbass A, Sheldon A, Gyra J, et al. Intensive short-term dynamic psychotherapy for DSM–IV personality disorders: a randomized controlled trial. Journal of Nervous and Mental Disease. 2008;196:211–216. [PubMed: 18340256]
  • Adli M, Baethge C, Heinz A, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? European Archives of Psychiatry and Clinical Neuroscience. 2005;255:387–400. [PubMed: 15868067]
  • AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Quality and Safety in Health Care. 2003;12:18–23. [PMC free article: PMC1743672] [PubMed: 12571340]
  • Ahn H, Wampold BE. Where oh where are the specific ingredients? A meta-analysis of component studies in counseling and psychotherapy. Journal of Counseling Psychology. 2001;48:251–257.
  • Akiskal HS. A developmental perspective on recurrent mood disorders: a review of studies in man. Psychopharmacology Bulletin. 1986;22:579–586. [PubMed: 3797565]
  • Almond S, Healey A. Mental health and absence from work. Work, Employment and Society. 2003;17:731–742.
  • Altman D, Bland M. Statistics notes: Diagnostic tests 2: predictive values. British Medical Journal. 1994;309:102. [PMC free article: PMC2540558] [PubMed: 8038641]
  • Altman D, Bland M. Statistics notes: Diagnostic tests 1: sensitivity and specificity. British Medical Journal. 1994;308:1552. [PMC free article: PMC2540489] [PubMed: 8019315]
  • Altshuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. American Journal of Psychiatry. 2001;158:1617–1622. [PubMed: 11578993]
  • American College of Sports Medicine. Guidelines for Graded Exercise Testing and Exercise Prescription. Madison, Wisconsin: American College of Sports Medicine; 1980.
  • Anderson IM, Edwards JG. Guidelines for choice of selective serotonin reuptake inhibitor in depressive illness. Advances in Psychiatric Treatment. 2001;7:170–180.
  • Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. 2000;14:3–20. [PubMed: 10757248]
  • Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. 2008;22:343–396. [PubMed: 18413657]
  • Andrews G, Jenkins R, editors. Management of Mental Disorders (UK edn, vol. 1). Sydney: WHO Collaborating Centre for Mental Health and Substance Misuse; 1999.
  • Andrews G, Anderson TM, Slade T, et al. Classification of anxiety and depressive disorders: problems and solutions. Depression and Anxiety. 2008;25:274–281. [PubMed: 18415950]
  • Anghelescu IG, Kohnen R, Szegedi A, et al. Comparison of hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomised multi-centre study. Pharmacopsychiatry. 2006;39:213–219. [PubMed: 17124643]
  • Angst J. Severity of depression and benzodiazepine co-medication in relationship to efficacy of antidepressants in acute trials: a meta-analysis of moclobemide trials. Human Psychopharmacology. 1993;8:401–407.
  • Angst J, Merikangas KR. Multi-dimensional criteria for the diagnosis of depression. Journal of Affective Disorders. 2001;62:7–15. [PubMed: 11172869]
  • Angst J, Preisig M. Course of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweizer Archiv für Neurologie und Psychiatrie. 1995;146:5–16. [PubMed: 7792568]
  • Angst J, Gamma A, Benazzi F, et al. Melancholia and atypical depression in the Zurich study: epidemiology, clinical characteristics, course, comorbidty and personality. Acta Psychiatrica Scandinavica. 2007;115(Suppl 433):72–84. [PubMed: 17280573]
  • APA. Diagnostic and Statistical Manual of Mental Disorders. 3. Washington, DC: APA; 1980. DSM–III.
  • APA. Diagnostic and Statistical Manual of Mental Disorders. 4. Washington, DC: APA; 1994. DSM–IV.
  • APA. Handbook of Psychiatric Measures. Washington, DC: APA; 2000.
  • APA. Practice guideline for the treatment of patients with major depressive disorder (revision) American Journal of Psychiatry. 2000;157(Suppl 4):1–45. [PubMed: 10767867]
  • APA. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: APA; 2000. (4th edn Text Revision) (DSM–IV-TR)
  • Aragones E, Pinol JL, Labad A. The overdiagnosis of depression in non-depressed patients in primary care. Family Practice. 2006;23:363–368. [PubMed: 16461446]
  • Aronson R, Offman HJ, Joffe RT, et al. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Archives of General Psychiatry. 1996;53:842–848. [PubMed: 8792761]
  • Arroll B, Goodyear-Smith F, Kerse N. Effect of the addition of a ‘help’ question to two screening questions on specificity for diagnosis of depression in general practice: diagnostic validation study. British Medical Journal. 2005;331:884–886. [PMC free article: PMC1255798] [PubMed: 16166106]
  • Association of the British Pharmaceutical Industry. Edronax (reboxetine) SPC. Compendium of Data Sheets and Summaries of Product Characteristics. 2003. SPC available at: http://www​.medicines​.org.uk/EMC/medicine​/8386/SPC/Edronax+4mg+Tablets/
  • Avery D, Winokur G. Mortality in depressed patients treated with electroconvulsive therapy and antidepressants. Archives of General Psychiatry. 1976;33:1029–1037. [PubMed: 962487]
  • Baca E, Garcia-Garcia M, Porras-Chavarino A. Gender differences in treatment response to sertraline versus imipramine in patients with nonmelancholic depressive disorders. Progressive Neuro-psychopharmacology and Biology Psychiatry. 2004;28:57–65. [PubMed: 14687858]
  • Badamgarav E, Weingarten SR, Henning JM, et al. Effectiveness of disease management programs in depression: a systematic review. American Journal of Psychiatry. 2003;160:2080–2090. [PubMed: 14638573]
  • Baer RA. Mindfulness training as a clinical intervention: a conceptual and empirical review. Clinical Psychology: Science and Practice. 2003;10:125–143.
  • Bailine SH, Rifkin A, Kayne E, et al. Comparison of bifrontal and bitemporal ECT for major depression. American Journal of Psychiatry. 2000;157:121–123. [PubMed: 10618025]
  • Baldomero EB, Ubago JG, Cercós CL, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depression and Anxiety. 2005;22:68–76. [PubMed: 16094658]
  • Baldwin DS, Cooper JA, Huusom AK, et al. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. International Journal of Clinical Psychopharmacology. 2006;21:159–169. [PubMed: 16528138]
  • Baldwin DS, Stein DJ, Dolberg OT, et al. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Human Psychopharmacology: Clinical and Experimental. 2009;24:269–275. [PubMed: 19334042]
  • Ballard C, Bannister C, Solis M, et al. The prevalence, associations and symptoms of depression amongst dementia sufferers. Journal of Affective Disorders. 1996;36:135–144. [PubMed: 8821316]
  • Barber JP, Crits-Christoph P, Luborsky L. Effects of therapist adherence and competence on patient outcome in brief dynamic therapy. Journal of Consulting and Clinical Psychology. 1996;64:619–622. [PubMed: 8698958]
  • Barber JP, Gallop R, Crits-Christoph P, et al. The role of therapist adherence, therapist competence, and the alliance in predicting outcome of individual drug counseling: results from the NIDA Collaborative Cocaine Treatment Study. Psychotherapy Research. 2006;16:229–240.
  • Barbey JT, Roose SP. SSRI safety in overdose. Journal of Clinical Psychiatry. 1998;59(Suppl 15):42–48. [PubMed: 9786310]
  • Barbosa L, Berk M, Vorster M. A double-blind, randomised, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. Journal of Clinical Psychiatry. 2003;64:403–407. [PubMed: 12716240]
  • Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials. British Journal of Psychiatry. 2001;178:129–144. [PubMed: 11157426]
  • Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. Canadian Medical Association Journal. 2009;180:291–297. [PMC free article: PMC2630355] [PubMed: 19188627]
  • Barkow K, Heun R, Wittchen HU, et al. Mixed anxiety-depression in a 1 year follow-up study: shift to other diagnoses or remission? Journal of Affective Disorders. 2004;79:235–239. [PubMed: 15023500]
  • Barrett JE, Williams JW, Oxman TE, et al. The treatment effectiveness project. A comparison of the effectiveness of paroxetine, problem-solving therapy, and placebo in the treatment of minor depression and dysthymia in primary care patients: background and research plan. General Hospital Psychiatry. 1999;21:260–273. [PubMed: 10514950]
  • Barrett JE, Williams JW Jr, Oxman TE, et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. Journal of Family Practice. 2001;50:405–412. [PubMed: 11350703]
  • Bauer MS, Dunner DL. Validity of seasonal pattern as a modifier for recurrent mood disorders for DSM–IV. Comprehensive Psychiatry. 1993;34:159–170. [PubMed: 8339533]
  • Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. The World Journal of Biological Psychiatry. 2002;3:5–43. [PubMed: 12479086]
  • Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. The World Journal of Biological Psychiatry. 2002;3:69–86. [PubMed: 12479080]
  • Beck AT. The past and future of cognitive therapy. Journal of Psychotherapy Practice and Research. 1997;6:276–284. [PMC free article: PMC3330473] [PubMed: 9292441]
  • Beck AT. The evolution of the cognitive model of depression and its neurobiological correlates. American Journal of Psychiatry. 2008;165:969–977. [PubMed: 18628348]
  • Beck AT, Beck JS. The Personality Belief Questionnaire. University of Pennsylvania; 1991.
  • Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Archives of General Psychiatry. 1961;4:561–571. [PubMed: 13688369]
  • Beck AT, Rush AJ, Shaw BF, et al. Cognitive Therapy of Depression. New York: Wiley; 1979.
  • Beck AT, Steer A, Brown GK. Beck Depression Inventory Manual. 2. San Antonio, Texas: The Psychological Corporation; 1996.
  • Beck AT, Guth D, Steer RA, et al. Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for primary care. Behaviour Research and Therapy. 1997;35:785–791. [PubMed: 9256522]
  • Beck AT, Steer RA, Brown GK. BDI-Fast Screen for Medical Patients: Manual. San Antonio, Texas: The Psychological Corporation; 2000.
  • Beck JS. Cognitive Therapy: Basics and Beyond. New York: Guilford Press; 1995.
  • Beekman AFT, Copeland JRM, Prince MJ. Review of community prevalence of depression in later life. British Journal of Psychiatry. 1999;174:307–311. [PubMed: 10533549]
  • Benedicte Á, Arellano J, De Cock E, et al. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. Journal of Affective Disorders. 2010;120:94–104. [PubMed: 19497623]
  • Benkert O, Szegedi A, Wetzel H, et al. 233233. This is also the reference for Benkert et al., 1997 (2nd cf). Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatrica Scandinavica. 1997;95:288–296. [PubMed: 9150822]
  • Bennett KJ, Torrance GW, Boyle MH, et al. Cost-utility analysis in depression: the McSad utility measure for depression health states. Psychiatric Services. 2000;51:1171–1176. [PubMed: 10970923]
  • Berlanga C, Flores-Ramos M. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. Journal of Affective Disorders. 2006;95:119–123. [PubMed: 16782204]
  • Berlin JA. Does blinding of readers affect the results of meta-analyses? Lancet. 1997;350:185–186. [PubMed: 9250191]
  • Bhugra D, Cochrane R. Psychiatry in a multi-ethnic context, Psychiatry in Multicultural Britain. Bhugra D, Cochrane R, editors. London: Gaskell; 2001.
  • Bhui K, Bhugra D, Goldberg D. Cross-cultural validity of the Amritsar Depression Inventory and the General Health Questionnaire amongst English and Punjabi primary care attenders. Social Psychiatry and Psychiatric Epidemiology. 2000;35:248–254. [PubMed: 10939423]
  • Bhui K, Bhugra D, Goldberg D, et al. Cultural influences on the prevalence of common mental disorders, general practitioners’ assessments and help-seeking among Punjabi and English people visiting their general practitioner. Psychological Medicine. 2001;31:815–825. [PubMed: 11459379]
  • Bhui K, Stansfeld S, Hull S, et al. Ethnic variations in pathways to and use of specialist mental health services in the UK. British Journal of Psychiatry. 2003;182:105–116. [PubMed: 12562737]
  • Biddle L, Donovan JL, Gunnell D, et al. Young adults’ perceptions of GPs as a help source for mental distress: a qualitative study. British Journal of General Practice. 2006;56:924–931. [PMC free article: PMC1934052] [PubMed: 17132380]
  • Biddle S, Fox K, Edmund L. Physical Activity in Primary Care in England. London: Health Education Authority; 1994.
  • Black N. Why we need observational studies to evaluate the effectiveness of health care. British Medical Journal. 1996;312:1215–1218. [PMC free article: PMC2350940] [PubMed: 8634569]
  • Blackburn IM, Euson K, Bishop S. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. Journal of Affective Disorders. 1986;10:67–75. [PubMed: 2939125]
  • Blashki TG, Mowbray R, Davies B. Controlled trial of amitriptyline in general practice. British Medical Journal. 1971;1:133–138. [PMC free article: PMC1795147] [PubMed: 4923928]
  • Blom MB, Spinhoven P, Hoffman T, et al. Severity and duration of depression, not personality factors, predict short term outcome in the treatment of major depression. Journal of Affective Disorders. 2007;104:119–126. [PubMed: 17467059]
  • Boeck V, Overo KF, Svendsen O. Studies on acute toxicity and drug levels of citalopram in the dog. Acta Pharmacologica et Toxicologica. 1982;50:169–174. [PubMed: 6953747]
  • Bogetto F, Bellino S, Revello RB, et al. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS Drugs. 2002;16:273–283. [PubMed: 11945110]
  • Bollini P, Pampallona S, Tibaldi G, et al. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry. 1999;174:297–303. [PubMed: 10533547]
  • Bordin ES. The generalizability of the psychoanalytic concept of the working alliance. Psychotherapy: Theory, Research and Practice. 1979;16:252–260.
  • Borghi J, Guest JF. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. European Psychiatry. 2000;15:378–387. [PubMed: 11004733]
  • Bostwick JM, Pankratz VS. Affective disorders and suicide risk: a reexamination. American Journal of Psychiatry. 2000;157:1925–1932. [PubMed: 11097952]
  • Bower P, Gilbody S. Stepped care in psychological therapies: access, effectiveness and efficiency: narrative literature review. British Journal of Psychiatry. 2005;186:11–17. [PubMed: 15630118]
  • Bower P, Sibbald B. On-site mental health workers in primary care: effects on professional practice, Cochrane Database of Systematic Reviews. 2000. Available at: http://www​.cochrane.org​/reviews/en/ab000532.html. [PubMed: 10908476]
  • Bower P, Byford S, Sibbald B, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy, and usual general practitioner care for patients with depression. II: Cost-effectiveness. British Medical Journal. 2000;321:1389–1392. [PMC free article: PMC27543] [PubMed: 11099285]
  • Bower P, Rowland N, Hardy R. The clinical effectiveness of counselling in primary care: a systematic review and meta-analysis. Psychological Medicine. 2003;33:203–215. [PubMed: 12622300]
  • Bower P, Gilbody S, Richards D, et al. Collaborative care for depression in primary care. Making sense of a complex intervention: systematic review and meta-regression. British Journal of Psychiatry. 2006;189:484–493. [PubMed: 17139031]
  • Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3:77–101.
  • Bridges KW, Goldberg DP. Somatic presentations of depressive illness in primary care, The Presentation of Depression: Current Approaches. Freeling P, Downey LJ, Malkin JC, editors. London: Royal College of General Practitioners; 1987. pp. 9–11.
  • Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479–500. [PubMed: 10977389]
  • British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF 45). London: British Medical Association and the Royal Pharmaceutical Society of Great Britain; 2003.
  • British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF 56). London: British Medical Association and the Royal Pharmaceutical Society of Great Britain; 2008.
  • British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF 57). London: British Medical Association and the Royal Pharmaceutical Society of Great Britain; 2009.
  • Brosan L, Moore R, Reynolds S. Factors associated with competence in cognitive therapists. Behavioural and Cognitive Psychotherapy. 2007;35:179–190.
  • Brotman MA, Strunk DR, DeRubeis RJ. Therapeutic alliance and adherence in cognitive therapy for depression. 2009 In preparation.
  • Brown G, Harris T. The Social Origins of Depression: A Study of Psychiatric Disorder in Women. London: Tavistock Publications; 1978.
  • Brown TA, Campbell LA, Lehman CL, et al. Current and lifetime comorbidity of the DSM–IV anxiety and mood disorders in a large clinical sample. Journal of Abnormal Psychology. 2001;110:585–599. [PubMed: 11727948]
  • Bryant MJ, Simons AD, Thase ME. Therapist skill and patient variables in homework compliance: controlling an uncontrolled variable in cognitive therapy outcome research. Cognitive Therapy and Research. 1999;23:381–399.
  • Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of UK mortality data. British Medical Journal. 2002;325:1332–1333. [PMC free article: PMC137809] [PubMed: 12468481]
  • Buckley NA, Dawson AH, Whyte IM, et al. Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet. 1994;343:159–162. [PubMed: 7904010]
  • Bucknall C, Brooks D, Curry PV, et al. Mianserin and trazodone for cardiac patients with depression. European Journal of Clinical Pharmacology. 1988;33:565–569. [PubMed: 3284752]
  • Burns DD. Feeling Good: the New Mood Therapy. New York: William Morrow; 1980.
  • Burns DD, Nolen-Hoeksema S. Therapeutic empathy and homework compliance in cognitive-behavioral therapy. Journal of Consulting and Clinical Psychology. 1992;60:441–449. [PubMed: 1619098]
  • Burroughs H, Morley M, Lovell K, et al. ‘Justifiable depression’: how health professionals and patients view late-life depression; a qualitative study. Family Practice. 2006;23:369–377. [PubMed: 16476699]
  • Byford S, Knapp M, Greenshields J, et al. Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach. Psychological Medicine. 2003;33:977–986. [PubMed: 12946082]
  • Cahill J, Barkham M, Hardy G, et al. Outcomes of patients completing and not completing cognitive therapy for depression. British Journal of Clinical Psychology. 2003;42:133–143. [PubMed: 12828803]
  • Cameron DE. The day hospital. An experimental form of hospitalisation for psychiatric patients. Modern Hospital. 1947;68:60–62. [PubMed: 20259355]
  • Campbell M, Fitzpatrick R, Haines A, et al. Framework for design and evaluation of complex interventions to improve health. British Medical Journal. 2000;321:694–696. [PMC free article: PMC1118564] [PubMed: 10987780]
  • Carcone B, Vial T, Chaillet N, et al. Symptomatic bradycardia caused by mianserin at therapeutic doses. Human Experimental Toxicology. 1991;10:383–384. [PubMed: 1683554]
  • Carels R, Darby L, Cacciapaglia H, et al. Applying a stepped-care approach to the treatment of obesity. Journal of Psychosomatic Research. 2005;59:375–383. [PubMed: 16310019]
  • Carney RM, Freedland KE, Sheline YI, et al. Depression and coronary heart disease: a review for cardiologists. Clinical Cardiology. 1997;20:196–200. [PubMed: 9068903]
  • Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386–389. [PubMed: 12869766]
  • Cassano P, Fava M. Depression and public health: an overview. Journal of Psychosomatic Research. 2002;53:849–857. [PubMed: 12377293]
  • Catalano G, Catalano MC, Epstein MA, et al. QTc interval prolongation associated with citalopram overdose: a case report and literature review. Clinical Neuropharmacology. 2001;24:158–162. [PubMed: 11391127]
  • Chew-Graham CA, May CR, Cole H, et al. The burden of depression in primary care: a qualitative investigation of general practitioners’ constructs of depressed people in primary care. Primary Care Psychiatry. 2000;6:137–141.
  • Chew-Graham CA, Bashir C, Chantler K, et al. South Asian women, psychological distress and self-harm: lessons for primary care trusts. Health and Social Care in the Community. 2002;10:339–347. [PubMed: 12390220]
  • Chew-Graham CA, Lovell K, Roberts C, et al. A randomized controlled trial to test the feasibility of a collaborative care model for the management of depression in older people. British Journal of General Practice. 2007;57:364–369. [PMC free article: PMC2047010] [PubMed: 17504586]
  • Chew-Graham CA, Chamberlain E, Turner K, et al. General practitioners’ and health visitors’ views on the diagnosis and management of postnatal depression: a qualitative study. British Journal of General Practice. 2008;58:169–176. [PMC free article: PMC2249792] [PubMed: 18399021]
  • Chong SA, Mythily S, Mahendran R. Cardiac effects of psychotropic drugs. Annals, Academy of Medicine, Singapore. 2001;30:625–631. [PubMed: 11817292]
  • Christensen H, Griffiths KM, Korten A. Web-based cognitive behaviour therapy: analysis of site usage and changes in depression and anxiety scores. Journal of Medical Internet Research. 2002;4:e3. [PMC free article: PMC1761927] [PubMed: 11956035]
  • Christensen H, Griffiths KM, Jorm A. Delivering interventions for depression by using the internet: randomised controlled trial. British Medical Journal. 2004;328:265–268. [PMC free article: PMC324455] [PubMed: 14742346]
  • Christian JL, O’Leary KD, Vivian D. Depressive symptomatology in maritally discordant women and men: the role of individual and relationship variables. Journal of Family Psychiatry. 1994;8:32–42.
  • Cipriani A, Furukawa TA, Geddes JR, et al. Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. Journal of Clinical Psychiatry. 2008;69:1732–1742. [PubMed: 19026250]
  • Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new generation antidepressants: a multiple treatments meta-analysis. The Lancet. 2009;373:746–758. [PubMed: 19185342]
  • Clark DM, Layard R, Smithies R. Improving Access to Psychological Therapy: Initial Evaluation of the Two Demonstration Sites, CEP Discussion Papers, dp0897. London: Centre for Economic Performance, LSE; 2008.
  • Cochrane Collaboration. Review Manager (RevMan) Version 4.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. [Computer programme]; 2003.
  • Cochrane Collaboration. Review Manager (RevMan) Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. [Computer programme]; 2008.
  • Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medication: association with use of tricyclic agents. American Journal of Medicine. 2000;108:2–8. [PubMed: 11059434]
  • Cole J, McGuffin P, Farmer AE. The classification of depression: are we still confused? British Journal of Psychiatry. 2008;192:83–85. [PubMed: 18245018]
  • Commander MJ, Sashidharan SP, Odell SM, et al. Access to mental health care in an inner city health district, I: Pathways into and within specialist psychiatric services. British Journal of Psychiatry. 1997;176:407–411. [PubMed: 9246247]
  • Committee on Safety of Medicines. Reminder: St John’s wort (hypericum perforatum) interactions. Current Problems in Pharmacovigilance. 2000;26:6–7.
  • Conradi HJ, de Jonge P, Ormel J. Prediction of the three-year course of recurrent depression in primary care patients: different risk factors for different outcomes. Journal of Affective Disorders. 2008;105:267–271. [PubMed: 17574685]
  • Cooper-Patrick L, Powe NR, Jenckes MW, et al. Identification of patient attitudes and preferences regarding treatment of depression. Journal of General Internal Medicine. 1997;12:431–438. [PMC free article: PMC1497133] [PubMed: 9229282]
  • Coryell W, Akiskal H, Leon AC, et al. The time course of nonchronic major depressive disorder. Uniformity across episodes and samples. National Institute of Mental Health Collaborative Program in the Psychobiology of Depression – Clinical Studies. Archives of General Psychiatry. 1994;51:405–410. [PubMed: 8179464]
  • Cowen PJ. Pharmacological management of treatment resistant depression. Advances in Psychiatric Treatment. 1998;4:320–327.
  • Coyne JC, Pepper CM, Flynn H. Significance of prior episodes of depression in two patient populations. Journal of Consulting and Clinical Psychology. 1999;67:76–81. [PubMed: 10028211]
  • Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. British Medical Journal. 2008;337:a1655. [PMC free article: PMC2769032] [PubMed: 18824488]
  • Creed F, Black D, Anthony P, et al. Randomised controlled trial of day patient versus inpatient psychiatric treatment. British Medical Journal. 1990;300:1033–1037. [PMC free article: PMC1662770] [PubMed: 2188696]
  • Creed F, Marks B. Liaison psychiatry in general practice: a comparison of the liaison-attachment scheme and shifted outpatient clinic models. Journal of the Royal College of General Practice. 1989;39:514–517. [PMC free article: PMC1712187] [PubMed: 2558209]
  • Crowther RE, Marshall M, Bond GR, et al. Helping people with severe mental illness to obtain work: systematic review. British Medical Journal. 2001;322:204–208. [PMC free article: PMC26585] [PubMed: 11159616]
  • Cuijpers P. Bibliotherapy in unipolar depression: a meta-analysis. Journal of Behavioural Therapy and Experimental Psychiatry. 1997;28:139–147. [PubMed: 9194011]
  • Cuijpers P, Smit F, van Straten A. Psychological treatments of subthreshold depression: a meta-analytic review. Acta Psychiatrica Scandinavica. 2007;115:434–444. [PubMed: 17498154]
  • Cuijpers P, van Straten A, van Oppen P, et al. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. Journal of Clinical Psychiatry. 2008;69:1675–1685. [PubMed: 18945396]
  • Cuijpers P, van Straten A, Warmerdam L, et al. Psychological treatmeant of depression: a meta-analytic database of randomized studies. BMC Psychiatry. 2008;8:36–41. [PMC free article: PMC2408566] [PubMed: 18485191]
  • Cullen JM, Mitchell P, Brodaty H, et al. Carbamazepine for treatment-resistant melancholia. Journal of Clinical Psychiatry. 1991;52:472–476. [PubMed: 1744065]
  • Cullen JM, Spates CR, Pagoto S, et al. Behavioral activation treatment for major depressive disorder: a pilot investigation. The Behavior Analyst Today. 2006;7:151–166.
  • Curtis L. Unit Costs of Health and Social Care 2008. Canterbury: Personal Social Services Research Unit, University of Kent; 2009.
  • Dago PL, Quitkin FM. Role of the placebo response in the treatment of depressive disorders. CNS Drugs. 1995;4:335–340.
  • Darling C, Tyler P. Brief encounters in general practice: liaison in general practice psychiatry clinics. Psychiatric Bulletin. 1990;14:592–594.
  • David D, Szentagotai A, Lupu V, et al. Rational emotive behavior therapy, cognitive therapy, and medication in the treatment of major depressive disorder: a randomized clinical trial, posttreatment outcomes, and six-month follow-up. Journal of Clinical Psychology. 2008;64:728–746. [PubMed: 18473339]
  • Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Research. 1986;17:87–95. [PubMed: 3083445]
  • Davidson K, Scott J, Schmidt U, et al. Therapist competence and clinical outcome in the prevention of parasuicide by manual assisted cognitive behaviour therapy trial: the POPMACT study. Psychological Medicine. 2004;34:855–863. [PubMed: 15500306]
  • Davis LL, Kabel D, Patel D, et al. Valproate as an antidepressant in major depressive disorder. Psychopharmacology Bulletin. 1996;32:647–652. [PubMed: 8993086]
  • Davison GC. Stepped care: doing more with less? Journal of Consulting and Clinical Psychology. 2000;68:580–585. [PubMed: 10965633]
  • Delgrado PL. Monoamine depletion studies: implications for antidepressant discontinuation syndrome. Journal of Clinical Psychiatry. 2006;67(Suppl 4):22–26. [PubMed: 16683859]
  • De Los Reyes A, Kazdin AE. When the evidence says, ‘Yes, no, and maybe so’: attending to and interpreting inconsistent findings among evidence-based interventions. Current Directions in Psychological Science. 2008;17:47–51. [PMC free article: PMC3021137] [PubMed: 21243087]
  • Del Piccolo L, Saltini A, Zimmermann C. Which patients talk about stressful life events and social problems to the general practitioner? Psychological Medicine. 1998;28:1289–1299. [PubMed: 9854270]
  • Department of Health. National Service Framework for Mental Health. London: Department of Health; 1999.
  • Department of Health. The NHS Plan A Plan for Investment A Plan for Reform. London: HMSO; 2000.
  • Department of Health. Exercise Referral Systems: A National Quality Assurance Framework. London: Department of Health; 2001.
  • Department of Health. Fast-forwarding Primary Care Mental Health: Graduate Primary Care Mental Health Workers – Best Practice Guidance. London: Department of Health; 2003.
  • Department of Health. Quality and Outcomes Framework: Guidance. London: Department of Health; 2004.
  • Department of Health. Improving Access to Psychological Therapies: Specification for the Commissioner-led Pathfinder Programme. London: Department of Health; 2007.
  • Department of Health. Prescription Cost Analysis: England 2007. London: Department of Health; 2008.
  • Department of Health. Report on Self Reported Experience of Patients From Black and Minority Ethnic Groups. London: Department of Health; 2008.
  • Department of Health & Social Care Institute for Excellence. SCIE Guide 30: Think Child, Think Parent, Think Family: a Guide to Parental Mental Health and Child Welfare. London: Department of Health; 2009.
  • Department of Health, Social Care Institute for Excellence & Care Services Improvement Partnership. Care Programme Approach (CPA) Briefing: Parents with Mental Health Problems and Their Children. 2008. http://www​.cpaa.co.uk/cpa-briefing.
  • Derogatis LR. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behavioral Science. 1974;19:1–15. [PubMed: 4808738]
  • DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986;7:177–188. [PubMed: 3802833]
  • DeRubeis RJ, Feeley M. Determinants of change in cognitive therapy for depression. Cognitive Therapy and Research. 1990;14:469–482.
  • DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy versus medications in the treatment of moderate to severe depression. Archives of General Psychiatry. 2005;62:409–416. [PubMed: 15809408]
  • Dick P, Cameron L, Cohen D, et al. Day and full-time psychiatric treatment: a controlled comparison. British Journal of Psychiatry. 1985;147:246–249. [PubMed: 4063589]
  • Dietrich DE, Emrich HM. The use of anticonvulsants to augment antidepressant medication. Journal of Clinical Psychiatry. 1998;59(Suppl 5):51–58. [PubMed: 9635548]
  • Dolan P, Williams A. A Social Tariff for EuroQol: Results from a UK General Population Survey. York: Centre for Health Economics, University of York; 1995.
  • Dombrovski AY, Mulsant BH, Houck PR, et al. Residual symptoms and recurrence during maintenance treatment of late-life depression. Journal of Affective Disorders. 2007;103:77–82. [PMC free article: PMC2680091] [PubMed: 17321595]
  • Donoghue J. Antidepressant use patterns in clinical practices: comparisons among tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica. 2000;101(Suppl 403):57–61. [PubMed: 11019936]
  • Donoghue J, Hylan TR. Antidepressant use in clinical practice: efficacy v. effectiveness. British Journal of Psychiatry. 2001;179(Suppl 42):9–17. [PubMed: 11532821]
  • Donoghue J, Tylee A. The treatment of depression: prescribing patterns of antidepressants in primary care in the UK. British Journal of Psychiatry. 1996;168:164–168. [PubMed: 8837905]
  • Donoghue J, Tylee A, Wildgust H. Cross-sectional database analysis of antidepressant prescribing in general practice in the UK, 1993–1995. British Medical Journal. 1996;313:861–862. [PMC free article: PMC2359032] [PubMed: 8870576]
  • Dornseif BE, Dunlop SR, Potvin JH, et al. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacology Bulletin. 1989;25:71–79. [PubMed: 2672072]
  • Dowrick CF. Beyond Depression. Oxford; Oxford University Press; 2004.
  • Dowrick C, Dunn G, Ayuso-Mateos JT, et al. Problem solving treatment and group psychoeducation for depression: multicentre randomised controlled trial. British Medical Journal. 2000;321:1450–1454. [PMC free article: PMC27549] [PubMed: 11110739]
  • Doyle JJ, Casciano J, Arikian S, et al. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value in Health. 2001;4:16–31. [PubMed: 11704969]
  • Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Structure and Function. 2008;213:93–118. [PMC free article: PMC2522333] [PubMed: 18704495]
  • Drummond MF, Jefferson TO. on behalf of the BMJ Economic Evaluation Working Party. Guidelines for authors and peer reviewers of economic submissions to the BMJ. British Medical Journal. 1996;313:275–283. [PMC free article: PMC2351717] [PubMed: 8704542]
  • Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed outpatients. British Journal of Psychiatry. 1991;159:394–398. [PubMed: 1835664]
  • Dunn RL, Donoghue JM, Ozminkowski RJ, et al. Longitudinal patterns of antidepressant prescribing in primary care in the UK: comparison with treatment guidelines. Journal of Psychopharmacology. 1999;13:136–143. [PubMed: 10475718]
  • Dwamena B. MIDAS: Stata Module for Meta-analytical Integration of Diagnostic Test Accuracy Studies, Statistical Software Components S456880. Boston, Massachusetts: Boston College Department of Economics; 2007.
  • Eagles JM, Wileman SM, Cameron IM, et al. Seasonal affective disorder among primary care attenders and a community sample in Aberdeen. British Journal of Psychiatry. 1999;175:472–475. [PubMed: 10789281]
  • Eccles M, Freemantle N, Mason J. North of England evidence-based guideline development project: methods of developing guidelines for efficient drug use in primary care. British Medical Journal. 1998;316:1232–1235. [PMC free article: PMC1112989] [PubMed: 9553004]
  • Edwards JG, Goldie A. Mianserin, maprotiline and intracardiac conduction. British Journal of Clinical Pharmacology. 1983;15(Suppl 2):249–254. [PMC free article: PMC1427885] [PubMed: 6824556]
  • Egan G. The Skilled Helper: A Systematic Approach to Effective Helping. Pacific Grove, California: Brooks/Cole; 1990.
  • Einarson TR, Arikian SR, Casciano J, et al. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomised controlled trials. Clinical Therapeutics. 1999;21:296–308. [PubMed: 10211533]
  • Ekers D, Richards D, Gilbody S. A meta-analysis of randomized trials of behavioural treatment of depression. Psychological Medicine. 2007;38:611–623. [PubMed: 17903337]
  • Elgie R. A patient and primary care perspective: a patient’s perspective on the treatment of depression. Journal of Clinical Psychiatry. 2006;67(Suppl 6):38–40. [PubMed: 16848676]
  • Eli Lilly and Co. Ltd. Cymbalta. Summary of Product Characteristics. Basingstoke: Eli Lilly; 2009. Available at: http://www​.medicines​.org.uk/emc/medicine/15694.
  • Elkin I. The NIMH treatment of depression collaborative research programme: where we began and where we are, Handbook of Psychotherapy and Behaviour Change. 4. Bergin AE, Garfield SL, editors. New York: Wiley; 1994.
  • Elkin I, Shea MT, Watkins J, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Programme. General effectiveness of treatments. Archives of General Psychiatry. 1989;46:971–982. [PubMed: 2684085]
  • Ellis AE. Reason and Emotion in Psychotherapy: A Comprehensive Method of Treating Human Disturbances: Revised and Updated. Secaucus, New Jersey: Carol Publishing Corporation; 1962.
  • Ellis CG. Chronic unhappiness: investigating the phenomenon in family practice. Canadian Family Physician. 1996;42:645–651. [PMC free article: PMC2146397] [PubMed: 8653032]
  • Emery G. Cognitive therapy with the elderly. In: Emery G, Hollon SD, Bedrosian RC, editors. New Directions in Cognitive Therapy. New York: Guilford Press; 1981. pp. 84–98.
  • Evans C, Mellor-Clark J, Margison F, et al. Clinical Outcomes in Routine Evaluation: The CORE-OM. Journal of Mental Health. 2000;9:247–255.
  • Faravelli C, Servi P, Arends JA, et al. Number of symptoms, quantification and qualification of depression. Comprehensive Psychiatry. 1996;37:307–315. [PubMed: 8879904]
  • Fava GA, Ruini C, Rafanelli C, et al. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. The American Journal of Psychiatry. 2004;161:1872–1876. [PubMed: 15465985]
  • Fava M, Kendler K. Major depressive disorder. Neuron. 2000;28:335–341. [PubMed: 11144343]
  • Fava M, Mulroy R, Alpert J, et al. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. American Journal of Psychiatry. 1997;154:1760–1762. [PubMed: 9396960]
  • Feeley M, DeRubeis RJ, Gelfand LA. The temporal relation of adherence and alliance to symptom change in cognitive therapy for depression. Journal of Consulting and Clinical Psychology. 1999;67:578–582. [PubMed: 10450629]
  • Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. Journal of Clinical Psychiatry. 1995;56:574–579. [PubMed: 8530334]
  • Feighner JP, Boyer WF. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatrica Scandinavica Supplementum. 1989;350:125–129. [PubMed: 2530763]
  • Fergusson D, Doucette S, Glass KC, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. British Medical Journal. 2005;330:396–403. [PMC free article: PMC549110] [PubMed: 15718539]
  • Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics. 2005;23:155–167. [PubMed: 15748090]
  • Fischer JE, Bachmann LM, Jaeschke R. A readers’ guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Medicine. 2003;29:1043–1051. [PubMed: 12734652]
  • Fleishaker JC, Francom SF, Herman BD, et al. Lack of effect of reboxetine on cardiac repolarisation. Clinical Pharmacological Therapy. 2001;70:261–269. [PubMed: 11557914]
  • Fonagy P. Some complexities in the relationship of psychoanalytic theory to technique. Psychoanalytic Quarterly. 2003;72:13–47. [PubMed: 12616867]
  • Ford DE, Mead LA, Chang PP, et al. Depression is a risk factor for coronary artery disease in men: the precursors study. Archives of Internal Medicine. 1998;158:1422–1426. [PubMed: 9665350]
  • Frank E, Prien RF, Jarrett JB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Archives of General Psychiatry. 1991;48:851–855. [PubMed: 1929776]
  • Fredman SJ, Fava M, Kienke AS, et al. Partial response, non-response and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current ‘next-step’ practices. Journal of Clinical Psychiatry. 2000;61:403–408. [PubMed: 10901336]
  • Freud S. Mourning and Melancholia, The Standard Edition of the Complete Psychological Works of Sigmund Freud. Vol. 14. London: Hogarth Press; 1917. reprinted 1953–1974.
  • Friedli K, King MB, Lloyd M, et al. Randomised controlled assessment of non-directive psychotherapy versus routine general-practitioner care. Lancet. 1997;350:1662–1665. [PubMed: 9400510]
  • Friedli K, King MB, Lloyd M. The economics of employing a counsellor in general practice: analysis of data from a randomised controlled trial. British Journal of General Practice. 2000;50:276–283. [PMC free article: PMC1313674] [PubMed: 10897510]
  • Fulton B, Benfield P. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs. 1996;52:450–474. [PubMed: 8875133]
  • Furukawa TA, Kitamura T, Takahashi K. Time to recovery from an inception cohort with hitherto untreated unipolar major depressive episodes. British Journal of Psychiatry. 2000;177:331–335. [PubMed: 11116774]
  • Furukawa TA, McGuire H, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review. British Medical Journal. 2002;325:991–995. [PMC free article: PMC131022] [PubMed: 12411354]
  • Furukawa TA, Streiner DL, Young LT. Antidepressant and benzodiazepine for major depression (Cochrane Review), Cochrane Library. 4. Oxford: Update Software; 2002.
  • Furukawa TA, Fujita A, Harai H, et al. Definitions of recovery and outcomes of major depression: results from a 10-year follow up. Acta Psychiatrica Scandinavica. 2008;117:35–40. [PMC free article: PMC2253703] [PubMed: 17986318]
  • Garnier R, Azoyan P, Chataigner D, et al. Acute fluvoxamine poisoning. Journal of International Medical Research. 1993;21:197–208. [PubMed: 7906658]
  • Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Annals of Internal Medicine. 2008;149:734–750. [PubMed: 19017592]
  • Gask L, Goldberg D, Lesser AL, et al. Improving the psychiatric skills of the general practice trainee: an evaluation of a group training course. Medical Education. 1988;22:132–138. [PubMed: 3374414]
  • Gask L, Sibbald B, Creed F. Evaluating models of working at the interface between mental health services and primary care. British Journal of Psychiatry. 1997;170:6–11. [PubMed: 9068767]
  • Gask L, Rogers A, Oliver D, et al. Qualitative study of patients’ perceptions of the quality of care for depression in general practice. British Journal of General Practice. 2003;53:278–283. [PMC free article: PMC1314569] [PubMed: 12879827]
  • Geddes JR. Clinical trial design: horses for courses. World Psychiatry. 2009;8:28–29. [PMC free article: PMC2652895] [PubMed: 19293952]
  • Geddes JR, Freemantle N, Mason J, et al. Selective serotonin reuptake inhibitors (SSRIs) for depression (Cochrane Review), Cochrane Library. 1. Oxford: Update Software; 2002.
  • Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361:653–661. [PubMed: 12606176]
  • Geddes J, Carney S, Cowen P, et al. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361:799–808. [PubMed: 12642045]
  • Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. British Journal of Psychiatry. 2009;194:4–9. [PubMed: 19118318]
  • Gellatly J, Bower P, Hennessy S, et al. What makes self-help interventions effective in the management of depressive symptoms? Meta-analysis and meta-regression. Psychological Medicine. 2007;37:1217–1228. [PubMed: 17306044]
  • Gensichen J, Beyer M, Muth C, et al. Case management to improve major depression in primary health care: a systematic review. Psychological Medicine. 2006;36:7–14. [PubMed: 16356292]
  • Gerber PD, Barrett JE, Barrett JA, et al. The relationship of presenting physical complaints to depressive symptoms in primary care patients. Journal of General Internal Medicine. 1992;7:170–173. [PubMed: 1487765]
  • Gibbons RD, Hur K, Bhaumik DK, et al. The relationship between antidepressant medication use and rate of suicide. Archives of General Psychiatry. 2005;62:165–172. [PubMed: 15699293]
  • Gilbody S, Bower P, Fletcher J, et al. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Archives of Internal Medicine. 2006;166:2314–2321. [PubMed: 17130383]
  • Gilbody S, Richards D, Barkham M. Diagnosing depression in primary care using self completed instruments: UK validation of PHQ-9 and CORE-OM. British Journal of General Practice. 2007;57:650–652. [PMC free article: PMC2099671] [PubMed: 17688760]
  • Giles DE, Jarrett RB, Biggs MM, et al. Clinical predictors of recurrence in depression. American Journal of Psychiatry. 1989;146:764–767. [PubMed: 2729427]
  • Gitlin MJ, Weiner H, Fairbanks L, et al. Failure of T3 to potentiate tricyclic antidepressant response. Journal of Affective Disorders. 1987;13:267–272. [PubMed: 2960719]
  • Glassman AH. Citalopram toxicity. Lancet. 1997;350:818. [PubMed: 9298037]
  • Glassman AH, Shapiro PA. Depression and the course of coronary artery disease. American Journal of Psychiatry. 1998;155:4–11. [PubMed: 9433332]
  • Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients. Risk–benefit reconsidered. Journal of the American Medical Association. 1993;269:2673–2675. [PubMed: 8487453]
  • Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. Journal of the American Medical Association. 2002;288:701–709. [PubMed: 12169073]
  • Goeringer KE, Raymond L, Christian GD, et al. Post mortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases. Journal of Forensic Sciences. 2000;45:633–648. [PubMed: 10855970]
  • Goldberg DP, Bridges K. Somatic presentations of psychiatric illness in primary care settings. Journal of Psychosomatic Research. 1988;32:137–144. [PubMed: 3042995]
  • Goldberg D, Huxley P. Mental Illness in the Community: The Pathway to Psychiatric Care. London: Tavistock; 1980.
  • Goldberg DP, Huxley PJ. Common Mental Disorders: A Bio-Social Model. London: Tavistock/Routledge; 1992.
  • Goldberg DP, Williams P. A User’s Guide to the General Health Questionnaire. Windsor: NFER-Nelson; 1991.
  • Goldberg DP, Jenkins L, Millar T, et al. The ability of trainee general practitioners to identify psychological distress among their patients. Psychological Medicine. 1993;23:185–193. [PubMed: 8475207]
  • Goldberg DP, Privett M, Ustun B, et al. The effects of detection and treatment on the outcome of major depression in primary care: a naturalistic study in 15 cities. British Journal of General Practice. 1998;48:1840–1844. [PMC free article: PMC1313290] [PubMed: 10198504]
  • Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. American Journal of Psychiatry. 2005;162:656–662. [PubMed: 15800134]
  • Goodwin G. Neurobiological aetiology of mood disorders, New Oxford Textbook of Psychiatry. Gelder MG, Lopez-Ibor JJ, Andreasen N, editors. Oxford; Oxford University Press; 2000. pp. 711–719.
  • GRADE Working Group. Grading quality of evidence and strength of recommendations. British Medical Journal. 2004;328:1490–1497. [PMC free article: PMC428525] [PubMed: 15205295]
  • Grant C, Goodenough T, Harvey I, et al. A randomised controlled trial and economic evaluation of a referrals facilitator between primary care and the voluntary sector. British Medical Journal. 2000;320:419–423. [PMC free article: PMC27287] [PubMed: 10669447]
  • Grayer J, Rudge R. Recruitment: lessons on setting up primary care mental health teams. Health Service Journal. 2005;115(Suppl 13) [PubMed: 15825667]
  • Greenberg JR, Mitchell SA. Object Relations in Psychoanalytic Theory. Cambridge, Massachusetts: Harvard University Press; 1983.
  • Greene R, Pugh R, Roberts D. Black and Minority Ethnic Parents with Mental Health Problems and Their Children, Research Briefing No. 29. London: Social Care Institute for Excellence; 2008.
  • Greenhalgh J, Knight C, Hind D, et al. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modeling studies. Health Technology Assessment. 2005;9:9. [PubMed: 15774232]
  • Gregor KJ, Overhage JM, Coons SJ, et al. Selective serotonin reuptake inhibitor dose titration in the naturalistic setting. Clinical Therapeutics. 1994;16:306–315. [PubMed: 8062324]
  • Greist J, Mundt JC, Kobak K. Factors contributing to failed trials of new agents: can technology prevent some problems? Journal of Clinical Psychiatry. 2002;63(Suppl 2):8–13. [PubMed: 15453008]
  • Grundemar L, Wohlfart B, Lagerstedt C, et al. Symptoms and signs of severe citalopram overdose. Lancet. 1997;349:1602. [PubMed: 9174567]
  • Gunnell D, Ashby D. Antidepressants and suicide: what is the balance of benefit and harm? British Medical Journal. 2004;329:34–38. [PMC free article: PMC443451] [PubMed: 15231620]
  • Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. British Medical Journal. 2005;330:385–395. [PMC free article: PMC549105] [PubMed: 15718537]
  • Guthrie E, Moorey J, Margison F. Cost-effectiveness of brief psychodynamic-interpersonal therapy in high utilisers of psychiatric services. Archives of General Psychiatry. 1999;56:519–526. [PubMed: 10359466]
  • Guy W. Early Clinical Drug Evaluation Programme Assessment Manual for Psychopharmacology – Revised. Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH; 1976.
  • Haddad PM. Antidepressant discontinuation syndromes. Drug Safety. 2001;24:183–197. [PubMed: 11347722]
  • Haefeli WE, Schoenenberger RA, Scholer A. Recurrent ventricular fibrillation in mianserin intoxication. British Medical Journal. 1991;302:415–416. [PMC free article: PMC1676212] [PubMed: 2004160]
  • Hakkart-van Roijen L, van Straten A, Al M, et al. Cost-utility of brief psychological treatment for depression and anxiety. British Journal of Psychiatry. 2006;188:323–329. [PubMed: 16582058]
  • Hall WD, Lucke J. How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality? Australian and New Zealand Journal of Psychiatry. 2006;40:941–950. [PubMed: 17054562]
  • Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. British Medical Journal. 2003;326:1008–1011. [PMC free article: PMC154757] [PubMed: 12742921]
  • Hamilton JA, Grant M, Jensvold MF. Sex and treatment of depression, Psychopharmacology and Women: Sex, Gender and Hormones. Jensvold MF, Halbreich U, Hamilton JA, editors. Washington, DC: American Psychiatric Press; 1996. pp. 241–260.
  • Hamilton M. A rating scale for depression. Journal of Neurology and Neurosurgical Psychiatry. 1960;23:56–62. [PMC free article: PMC495331] [PubMed: 14399272]
  • Hammen C, Henry R, Daley SE. Depression and sensitisation to stressors among young women as a function of childhood adversity. Journal of Consulting and Clinical Psychology. 2000;68:782–787. [PubMed: 11068964]
  • Harden CL, Pulver MC, Ravdin LD, et al. A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy and Behavior. 2000;1:93–99. [PubMed: 12609137]
  • Haringsma R, Engels GI, Beekman ATF, et al. The criterion validity of the Center for Epidemiological Studies Depression Scale (CES-D) in a sample of self-referred elders with depressive symptomatology. International Journal of Geriatric Psychiatry. 2004;19:558–563. [PubMed: 15211536]
  • Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. British Journal of Psychiatry. 1997;170:205–228. [PubMed: 9229027]
  • Harris T. Introduction to the work of George Brown, Where Inner and Outer Worlds Meet: Psychosocial Research in the Tradition of George W Brown. Harris T, editor. London & New York: Routledge; 2000. pp. 1–52.
  • Harris T, Brown GW, Robinson R. Befriending as an intervention for chronic depression among women in an inner city. 1: Randomised controlled trial. British Journal of Psychiatry. 1999;174:219–224. [PubMed: 10448446]
  • Hayhurst H, Cooper Z, Paykel ES, et al. Expressed emotion and depression: a longitudinal study. British Journal of Psychiatry. 1997;171:439–443. [PubMed: 9463602]
  • Healey D. The emergence of antidepressant induced suicidality. Primary Care Psychiatry. 2003;6:23–28.
  • Health and Safety Executive. Self-Reported Work-Related Illness and Workplace Injuries in 2006/07: Results from the Labour Force Survey. Caerphilly: HSE Information Services; 2008.
  • Hemels MEH, Kasper S, Walter E, et al. Cost effectiveness of escitalopram versus citalopram in the treatment of severe depression. The Annals of Pharmacotherapy. 2004;38:954–960. [PubMed: 15113989]
  • Henkel V, Seemüller F, Obermeier M, et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. Journal of Affective Disorders. 2009;115:439–449. [PubMed: 19027961]
  • Henry JA, Antao CA. Suicide and fatal antidepressant poisoning. European Journal of Medicine. 1992;1:343–348. [PubMed: 1341462]
  • Herrmann LL, Ebmeier KP. Factors modifying the efficacy of transcranial magnetic stimulation in the treatment of depression. Journal of Clinical Psychiatry. 2006;67:1870–1876. [PubMed: 17194264]
  • Herz MI, Endicott J, Spitzer RL, et al. Day versus inpatient hospitalisation: a controlled study. American Journal of Psychiatry. 1971;127:1371–1382. [PubMed: 5549929]
  • Hewer W, Rost W, Gattaz WF. Cardiovascular effects of fluvoxamine and maprotiline antidepressant treatment: effects on cognitive function and psychomotor performance. International Clinical Psychopharmacology. 1995;15:305–318.
  • Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1, The Cochrane Collaboration. 2008. Available at: www​.cochrane-handbook.org.
  • Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine. 2002;21:1539–1558. [PubMed: 12111919]
  • Hildebrandt MG, Steyerberg EW, Stage KB, et al. Are gender differences important for the clinical effects of antidepressants? American Journal of Psychiatry. 2003;160:1643–1650. [PubMed: 12944340]
  • Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. International Clinical Psychopharmacology. 2000;15:305–318. [PubMed: 11110006]
  • Hippisley-Cox J, Pringle M, Hammersley V, et al. Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care. British Medical Journal. 2001;323:666–669. [PMC free article: PMC55927] [PubMed: 11566831]
  • Hla KK, Boyd O. Mianserin and complete heart block. Human Toxicology. 1987;6:401–402. [PubMed: 3679249]
  • Hollon SD, Evans MD, Auerbarch A, et al. Development of a system for rating therapies for depression: differentiating cognitive therapy, interpersonal psychotherapy, and clinical management. Unpublished manuscript. Nashville, Tennessee: Vanderbilt University; 1988.
  • Hollon SD, Stewart MO, Strunk D. Enduring effects for cognitive behavior therapy in the treatment of depression and anxiety. Annual Review of Psychology. 2005;57:285–315. [PubMed: 16318597]
  • Holm KJ, Spencer CM. Reboxetine: a review of its use in depression. CNS Drugs. 1999;12:65–83.
  • Holma KM, Holma IA, Melartin TK, et al. Long-term outcome of major depressive disorder in psychiatric patients is variable. Journal of Clinical Psychology. 2008;69:270–276. [PubMed: 18251627]
  • Holmes J. The Search for a Secure Base: Attachment Theory and Psychotherapy. London: Brunner-Routledge; 2001.
  • Hooley JM, Teasdale JD. Predictors of relapse in unipolar depressives: expressed emotion, marital distress and perceived criticism. Journal of Abnormal Psychology. 1989;98:229–235. [PubMed: 2768657]
  • Hopko DR, Lejuez CW, Ruggiero KJ, et al. Contemporary behavioural activation treatments for depression: procedures, principles, and progress. Clinical Psychology Review. 2003;23:699–717. [PubMed: 12971906]
  • Howe D. Attachment Theory for Social Work in Practice. Basingstoke: Palgrave; 1995.
  • Hunkeler EM, Meresman JF, Hargreaves WA, et al. Efficacy of nurse tele-health care and peer support in augmenting treatment of depression in primary care. Archives of Family Medicine. 2000;9:700–708. [PubMed: 10927707]
  • Hunkeler EM, Katon W, Tang L, et al. Long term outcomes from the IMPACT randomised trial for depressed elderly patients in primary care. British Medical Journal. 2006;332:259–263. [PMC free article: PMC1360390] [PubMed: 16428253]
  • Hurley SC. Lamotrigine update and its use in mood disorders. Annals of Pharmacotherapy. 2002;36:860–873. [PubMed: 11978166]
  • Husain N, Creed F, Tomenson B. Depression and social stress in Pakistan. Psychological Medicine. 2000;30:395–402. [PubMed: 10824659]
  • Husain N, Waheed W, Tomenson B, et al. The validation of personal health questionnaire amongst people of Pakistani family origin living in the United Kingdom. Journal of Affective Disorders. 2007;97:261–264. [PubMed: 16860397]
  • IAPT. IAPT Workforce Capacity Tool: Guidance for Use. 2009. [accessed May 2009]. Available at: http://www​.iapt.nhs.uk​/2008/01/17/workforce-capacity-tool/
  • Iliffe S, Haines A, Gallivan S, et al. Assessment of elderly people in general practice. 1. Social circumstances and mental state. British Journal of General Practice. 1991;41:9–12. [PMC free article: PMC1371476] [PubMed: 1805805]
  • Ingram A, Saling MM, Schweitzer I. Cognitive side effects of brief pulse electroconvulsive therapy: a review. Journal of ECT. 2008;24:3–9. [PubMed: 18379328]
  • Institute of Medicine (US), Board on Global Health & Committee on Nervous System Disorders in Developing Countries. Neurological, Psychiatric and Developmental Disorders: Meeting the Challenge in the Developing World. Washington, DC: National Academy Press; 2001.
  • Isacsson G, Holmgren P, Druid H, et al. The utilisation of antidepressants –a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992–1994. Acta Psychiatrica Scandinavica. 1997;96:94–100. [PubMed: 9272192]
  • Isacsson G, Boethius G, Henriksson S, et al. Selective serotonin reuptake inhibitors have broadened the utilisation of antidepressant treatment in accordance with recommendations. Findings from a Swedish prescription database. Journal of Affective Disorders. 1999;53:15–22. [PubMed: 10363662]
  • Isbister GK, Prior FH, Foy A. Citalopram-induced bradycardia and presyncope. The Annals of Pharmacotherapy. 2001;35:1552–1555. [PubMed: 11793617]
  • Jackson JL, Passamonti M, Kroenke K. Outcome and impact of mental disorders in primary care at 5 years. Psychosomatic Medicine. 2007;69:270–276. [PubMed: 17401055]
  • Jackson WK, Roose SP, Glassman AH. Cardiovascular toxicity of antidepressant medications. Psychopathology. 1987;20(Suppl 1):64–74. [PubMed: 3321132]
  • Jacobson NS, Fruzzetti A, Dobson KS, et al. Marital therapy as a treatment for depression II: The effects of relationship quality and therapy on depressive relapse. Journal of Consulting and Clinical Psychology. 1993;61:516–519. [PubMed: 8326054]
  • Jacobson NS, Martell CR, Dimidjian S. Behavioral activation therapy for depression: returning to contextual roots. Clinical Psychology: Science and Practice. 2001;8:255–270.
  • Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Controlled Clinical Trials. 1996;17:1–12. [PubMed: 8721797]
  • James IA, Blackburn I-M, Milne DL, et al. Moderators of trainee therapists’ competence in cognitive therapy. British Journal of Clinical Psychology. 2001;40:131–141. [PubMed: 11446235]
  • Janowsky D, Curtis G, Zisook S, et al. Trazodone-aggravated ventricular arrhythmias. Journal of Clinical Psychopharmacology. 1983;3:372–376. [PubMed: 6196381]
  • Jick H, Kaye JA, Jick SS. Antidepressants and the risk or suicidal behaviours. Journal of the American Medical Association. 2004;292:338–343. [PubMed: 15265848]
  • Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Research. 1990;32:241–251. [PubMed: 2201988]
  • Johnson J, Howarth E, Weissman MM. The validity of major depression with psychotic features based on a community sample. Archives of General Psychiatry. 1991;48:1075–1081. [PubMed: 1845225]
  • Johnston O, Kumar S, Kendall K, et al. Qualitative study of depression management in primary care: GP and patient goals, and the value of listening. British Journal of General Practice. 2007;57:e1–e14. [PMC free article: PMC2169333] [PubMed: 17976282]
  • Jones E, Asen E. Systemic Couple Therapy and Depression. London: Karnac; 1999.
  • Joy CB, Adams CE, Rice K. Crisis intervention for people with severe mental illnesses (Cochrane Review), Cochrane Library. 3. Oxford: Update Software; 2003.
  • Joyce PR, Mulder RT, Luty SE, et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Australian and New Zealand Journal of Psychiatry. 2002;36:384–391. [PubMed: 12060188]
  • Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Archives of General Psychiatry. 1998;55:694–700. [PubMed: 9707379]
  • Judge R, Parry MG, Quail D, et al. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. International Clinical Psychopharmacology. 2002;17:217–225. [PubMed: 12177584]
  • Kabat-Zinn J. Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness. New York: Dell Publishing; 1990.
  • Kahn E. Heinz Kohut and Carl Rogers: a timely comparison. American Psychologist. 1985;40:893–904.
  • Kaltenthaler E, Shackley P, Stevens K, et al. A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety. Health Technology Assessment. 2002;6:1–89. [PubMed: 12433315]
  • Kaltenthaler E, Parry G, Beverley C, et al. Computerised cognitive-behavioural therapy for depression: systematic review. British Journal of Psychiatry. 2008;193:181–184. [PubMed: 18757972]
  • Kanai T, Takeuchi H, Furukawa TA, et al. Time to recurrence after recovery from major depressive episodes and its predictors. Psychological Medicine. 2003;33:839–845. [PubMed: 12877398]
  • Kasper S, Wehr TA, Bartko JJ, et al. Epidemiological findings of seasonal changes in mood and behavior. A telephone survey of Montgomery County, Maryland. Archives of General Psychiatry. 1989;46:823–833. [PubMed: 2789026]
  • Kasper S, Volz HP, Möller A, et al. Continuation and long-term maintenance treatment with hypericum extract WS 5570 after recovery from an acute episode of moderate depression: a double-blind, randomized, placebo controlled long-term trial. European Neuropsychopharmacology. 2008;18:803–813. [PubMed: 18694635]
  • Katon W, von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Medical Care. 1992;30:67–76. [PubMed: 1729588]
  • Katon W, von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. Journal of the American Medical Association. 1995;273:1026–1031. [PubMed: 7897786]
  • Katon W, Robinson P, von Korff M, et al. A multifaceted intervention to improve treatment of depression in primary care. Archives of General Psychiatry. 1996;53:924–932. [PubMed: 8857869]
  • Katon W, von Korff M, Lin E, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomised trial. Archives of General Psychiatry. 1999;56:1109–1115. [PubMed: 10591288]
  • Katon W, von Korff M, Lin E, et al. Rethinking practitioner roles in chronic illness: the specialist, primary care physician and the practice nurse. General Hospital Psychiatry. 2001;23:138–144. [PubMed: 11427246]
  • Katon W, Russo J, von Korff M, et al. Long-term effects of a collaborative care intervention in persistently depressed primary care patients. Journal of General Internal Medicine. 2002;17:741–748. [PMC free article: PMC1495114] [PubMed: 12390549]
  • Katzelnick DJ, Simon GE, Pearson SD, et al. Randomised trial of a depression management programme in high utilisers of medical care. Archives of Family Medicine. 2000;9:345–351. [PubMed: 10776363]
  • Kazantzis N, Deane FP, Ronan KR. Homework assignments in cognitive and behavioral therapy: a meta-analysis. Clinical Psychology: Science and Practice. 2000;7:189–202.
  • Kazdin AE. Evidence-based treatment and practice: new opportunities to bridge clinical research and practice, enhance the knowledge base, and improve patient care. American Psychologist. 2008;63:146–159. [PubMed: 18377105]
  • Keller MB, Lavori PW, Rice J, et al. The persistent risk of chronicity in recurrent episodes of non-bipolar major depressive disorder: a prospective follow-up. American Journal of Psychiatry. 1986;143:24–28. [PubMed: 3942283]
  • Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the consortium for research in electroconvulsive therapy (CORE) Archives of General Psychiatry. 2007;63:1337–1344. [PMC free article: PMC3708140] [PubMed: 17146008]
  • Kendell RE. The Classification of Depressive Illness, Maudsley Monographs 18. 1. Oxford; Oxford Unversity Press: 1968.
  • Kendler L, Prescott C. A population-based twin study of lifetime major depression in men and women. Archives of General Psychiatry. 1999;56:39–44. [PubMed: 9892254]
  • Kendler KS, Gardner CO, Neale MC, et al. Genetic risk factors for major depression in men and women: similar or different heritabilities and same or partly distinct genes? Psychological Medicine. 2001;31:605–616. [PubMed: 11352363]
  • Kendrick T, Stevens L, Bryant A, et al. Hampshire depression project: changes in the process of care and cost consequences. British Journal of General Practice. 2001;51:911–913. [PMC free article: PMC1314148] [PubMed: 11761205]
  • Kendrick T, King F, Albertella L, et al. GP treatment decisions for patients with depression: an observational study. British Journal of General Practice. 2005;55:280–286. [PMC free article: PMC1463130] [PubMed: 15826435]
  • Kendrick T, Simons L, Mynors-Wallis L, et al. Cost-effectiveness of referral for generic care or problem-solving treatment from community mental health nurses, compared with usual general practitioner care for common mental disorders: randomised controlled trial. British Journal of Psychiatry. 2006;189:50–59. [PubMed: 16816306]
  • Kendrick T, Peveler R, Longworth L, et al. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial. British Journal of Psychiatry. 2006;188:337–345. [PubMed: 16582060]
  • Kendrick T, Chatwin J, Dowrick C, et al. Randomised controlled trial to determine the clinical effectiveness and cost effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technology Assessment. 2009;13:22. [PubMed: 19401066]
  • Kennedy N, Foy K. The impact of residual symptoms on outcome of major depression. Current Psychiatry Reports. 2005;7:441–446. [PubMed: 16318822]
  • Kessing LV. Epidemiology of subtypes of depression. Acta Psychiatrica Scandinavica. 2007;115(Suppl 433):85–89. [PubMed: 17280574]
  • Kessing LV, Anderson PK. Predictive effects of previous episodes on the risk of recurrence in depressive and bipolar disorders. Current Psychiatry Reports. 2005;7:413–420. [PubMed: 16318818]
  • Kessler D, Bennewith O, Lewis G, et al. Detection of depression and anxiety in primary care: follow up study. British Medical Journal. 2002;325:1016–1017. [PMC free article: PMC131021] [PubMed: 12411363]
  • Kessler RC, Greenberg PE, Mickelson KD, et al. The effects of chronic mental health conditions on work loss and work cut back. Journal of Occupational and Environmental Medicine. 2001;43:218–225. [PubMed: 11285869]
  • Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) Journal of the American Medical Association. 2003;289:3095–3105. [PubMed: 12813115]
  • Ketter TA, Post RM, Parekh PI, et al. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. Journal of Clinical Psychiatry. 1995;56:471–475. [PubMed: 7559374]
  • Khan A, Dager SR, Cohen S, et al. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology. 1991;4:125–130. [PubMed: 2025378]
  • Khan A, Leventhal R, Khan S, et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. Journal of Clinical Psychopharmacology. 2002;22:40–45. [PubMed: 11799341]
  • Khan N, Bower P, Rogers A. Guided self-help in primary care mental health: meta-synthesis of qualitative studies of patient experience. British Journal of Psychiatry. 2007;191:206–211. [PubMed: 17766759]
  • King M, Sibbald B, Ward E, et al. Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care. Health Technology Assessment. 2000;4:1–83. [PubMed: 11086269]
  • Kingdon D, Tyrer P, Seivewright N, et al. The Nottingham study of neurotic disorder: influence of cognitive therapists on outcome. British Journal of Psychiatry. 1996;169:93–97. [PubMed: 8818375]
  • Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. 1998. http://journals​.apa.org​/prevention/volume1/pre0010002a.html.
  • Kirsch I, Scoboria A. Apples, oranges, and placebos: heterogeneity in a meta-analysis of placebo effects. Advances in Mind-Body Medicine. 2001;17:307–309. [PubMed: 11931056]
  • Kirsch I, Moore TJ, Scoboria A, et al. The emperor’s new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. 2002. Available at: http://journals​.apa.org​/prevention/volume5/pre0050023a.html.
  • Kirsch I, Scoboria A, Moore TJ. Antidepressants and placebos: secrets, revelations, and unanswered questions. 2002. Available at: http://journals​.apa.org​/prevention/volume5/pre0050033r.html.
  • Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. Public Library of Science Medicine. 2008;5:260–268. [PMC free article: PMC2253608] [PubMed: 18303940]
  • Kisely S, Gater R, Goldberg DP. Results from the Manchester Centre, Mental Illness in General Health Care: An International Study. Üstün TB, Sartorius N, editors. Chichester: Wiley; 1995. pp. 175–191.
  • Klerman GL, Weissman MM, Rounsaville BJ, et al. Interpersonal Psychotherapy of Depression. New York: Basic Books; 1984.
  • Knapp M. Hidden costs of mental illness. British Journal of Psychiatry. 2003;183:477–478. [PubMed: 14645015]
  • Knapp M, Ilson S. Economic aspects of depression and its treatment. Current Opinion in Psychiatry. 2002;15:69–75.
  • Knekt P, Lindfors O, Harkanaen T, et al. Randomized trial on the effectiveness of long-and short-term psychodynamic psychotherapy and solution-focused therapy on psychiatric symptoms during a 3-year follow-up. Psychological Medicine. 2008;38:689–703. [PubMed: 18005493]
  • Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. American Journal of Psychiatry. 2000;157:1445–1452. [PubMed: 10964861]
  • Kornstein SG, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials. Journal of Clinical Psychiatry. 2006;67:761–770. [PubMed: 16841626]
  • Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. Journal of the American Academy of Child Adolescent Psychiatry. 1996;35:705–715. [PubMed: 8682751]
  • Kovacs M, Rush AT, Beck AT, et al. Depressed outpatients treated with cognitive therapy or pharmacotherapy: a one-year follow-up. Archives of General Psychiatry. 1981;38:33–39. [PubMed: 7006557]
  • Kris EB. Day hospitals. Current Therapeutic Research. 1965;7:320–323. [PubMed: 14286214]
  • Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-9: validity of a brief depression severity measure. Journal of General Internal Medicine. 2001;16:606–613. [PMC free article: PMC1495268] [PubMed: 11556941]
  • Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Medical Care. 2003;41:1284–1292. [PubMed: 14583691]
  • Krupinski J, Tiller JW. The identification and treatment of depression by general practitioners. Australian and New Zealand Journal of Psychiatry. 2001;35:827–832. [PubMed: 11990894]
  • Kuehner C. An evaluation of the ‘Coping with Depression Course’ for relapse prevention with unipolar depressed patients. Psychotherapy and Psychosomatics. 2005;74:254–259. [PubMed: 15947516]
  • Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride) American Journal of Psychiatry. 1958;115:459–464. [PubMed: 13583250]
  • Kupfer DJ. Long-term treatment of depression. Journal of Clinical Psychiatry. 1991;52(Suppl 5):28–34. [PubMed: 1903134]
  • Kuyken W, Tsivrikos D. Therapist competence, comorbidity and cognitive-behavioral therapy for depression. Psychotherapy and Psychosomatics. 2009;78:42–48. [PubMed: 19018156]
  • Kuyken W, Taylor RS, Barrett B, et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. Journal of Consulting and Clinical Psychology. 2008;76:966–978. [PubMed: 19045965]
  • Lam RW, Chan P, Wilkins-Ho M, et al. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and metaanalysis. Canadian Journal of Psychiatry. 2008;53:621–671. [PubMed: 18801225]
  • Lambert M, Ogles B. The efficacy and effectiveness of psychotherapy, Bergin and Garfield’s Handbook of Psychotherapy and Behavior Change. 5. Lambert NMJ, editor. New York: Wiley; 2004.
  • Lancaster SG, Gonzalez JP. Lofepramine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1989;37:123–140. [PubMed: 2649353]
  • Lau MA, Segal ZV, Williams JMG. Teasdale’s differential activation hypothesis: implications for mechanisms of depressive relapse and suicidal behaviour. Behaviour Research and Therapy. 2004;42:1001–1017. [PubMed: 15325898]
  • Lauritzen L, Odgaard K, Clemmesen L, et al. Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiatrica Scandinavica. 1996;94:241–251. [PubMed: 8911559]
  • Lave JR, Franks RG, Schulberg HC, et al. Cost-effectiveness of treatments for major depression in primary care practice. Archives of General Psychiatry. 1998;55:645–651. [PubMed: 9672056]
  • Lawson JS, Inglis J, Delva NJ, et al. Electrode placement in ECT: cognitive effects. Psychological Medicine. 1990;20:335–344. [PubMed: 2356258]
  • Layard R. The case for psychological treatment centres. British Medical Journal. 2006;332:1030–1032. [PMC free article: PMC1450056] [PubMed: 16644834]
  • Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in later life. Consensus statement update. Journal of the American Medical Association. 1997;278:1186–1190. [PubMed: 9326481]
  • Lee AS, Murray RM. The long-term outcome of Maudsley depressives. British Journal of Psychiatry. 1988;153:741–751. [PubMed: 3256373]
  • Leff J, Vearnals S, Brewin CR, et al. The London Depression Intervention Trial. Randomised controlled trial of antidepressants vs. couple therapy in the treatment and maintenance of people with depression living with a partner: clinical outcome and costs. British Journal of Psychiatry. 2000;177:95–100. [PubMed: 11026946]
  • Leichsenring F. Randomized controlled versus naturalistic studies: a new research agenda. Bulletin of the Menninger Clinic. 2004;68:137–151. [PubMed: 15262616]
  • Leichsenring F, Rabung S. Effectiveness of long-term psychodynamic psychotherapy: a meta-analysis. Journal of the American Medical Association. 2008;300:1551–1565. [PubMed: 18827212]
  • Leichsenring F, Rabung S, Leibing E. The efficacy of short-term psychodynamic psychotherapy in specific psychiatric disorders. A meta-analysis. Archives of General Psychiatry. 2004;61:1208–1216. [PubMed: 15583112]
  • Leith LM. Foundations of Exercise and Mental Health. Morgantown, West Virginia: Fitness Information Technology; 1994.
  • Lejoyeux M, Ades J. Antidepressant discontinuation: a review of the literature. Journal of Clinical Psychiatry. 1997;58(Suppl 7):11–15. [PubMed: 9219488]
  • Lejoyeux M, Ades J, Mourad I, et al. Antidepressant withdrawal syndrome: recognition, prevention and management. CNS Drugs. 1996;5:278–292.
  • Lenert LA. The reliability and internal consistency of an internet capable program for measuring utilities. Quality of Life Research. 2000;9:811–817. [PubMed: 11297023]
  • Lepine JP, Gastpar M, Mendlewicz J, et al. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society) International Clinical Psychopharmacology. 1997;12:19–29. [PubMed: 9179630]
  • Lepore SJ. Expressive writing moderates the relation between intrusive thoughts and depressive symptoms. Journal of Personality and Social Psychology. 1997;73:1030–1037. [PubMed: 9364758]
  • Letemendia FJJ, Delva NJ, Rodenburg M, et al. Therapeutic advantage of bifrontal electrode placement in ECT. Psychological Medicine. 1993;23:349–360. [PubMed: 8332652]
  • Lewinsohn PM. The behavioural study and treatment of depression, Progress in Behavior Modification. Hersen M, Eisler RM, Miller PM, editors. Vol. 1. New York: Academic Press; 1975. pp. 19–64.
  • Lewinsohn PM, Antonuccio DO, Steinmetz-Breckenridge JL, et al. The Coping with Depression Course: A Psychoeducational Intervention for Unipolar Depression. Eugene, Oregon: Castalia Publishing; 1984.
  • Lewinsohn PM, Munoz RF, Youngren MA, et al. Control Your Depression. 2. Englewood Cliffs, New Jersey: Prentice-Hall; 1986.
  • Lewinsohn PM, Clarke GN, Hoberman HM. The Coping with Depression course: review and future directions. Canadian Journal of Behavioral Science. 1989;21:470–493.
  • Lewinsohn PM, Solomon A, Seeley JR, et al. Clinical implications of ‘sub-threshold’ depressive symptoms. Journal of Abnormal Psychology. 2000;109:345–351. [PubMed: 10895574]
  • Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. British Medical Journal. 2003;326:1167–1170. [PMC free article: PMC156458] [PubMed: 12775614]
  • Licht RW, Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology. 2002;161:143–151. [PubMed: 11981594]
  • Linde K, Mulrow CD. St John’s wort for depression (Cochrane Review), Cochrane Library. 1. Chichester: Wiley; 2004.
  • Linde K, Berner MM, Kriston L, et al. St John’s Wort for major depression. Cochrane Database of Systematic Reviews 2008. 2008:CD000448. [PubMed: 18843608] [Cross Ref]
  • Lindert J, Schouler-Ocak M, Heinz A, et al. Mental health, health care utilisation of migrants in Europe. European Psychiatry. 2008;23(Suppl 1):14–20. [PubMed: 18371575]
  • Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatrica Scandinavica. 2002;105:164–172. [PubMed: 11939969]
  • Livingstone MG, Livingstone HM. Monoamine oxidase inhibitors: an update on drug interactions. Drug Safety. 1996;14:219–227. [PubMed: 8713690]
  • Loosen PT. The TRH stimulation test in psychiatric disorders: a review, Handbook of Clinical Psychoneuroendocrinology. Loosen PT, Nemeroff CB, editors. Chichester: Wiley; 1987. pp. 336–360.
  • Lovell K, Richards D. Multiple access points and levels of entry (MAPLE): ensuring choice, accessibility and equity for CBT services. Behavioural and Cognitive Psychotherapy. 2000;28:379–392.
  • Lovell K, Richards D. A Recovery Programme for Depression. London: Rethink; 2008.
  • Luborsky L, Singer B, Luborsky L. Comparative studies of psychotherapies: is it true that ‘everyone has won and all must have prizes’? Archives of General Psychiatry. 1975;32:995–1008. [PubMed: 239666]
  • Lundbeck Ltd. Cipralex. Summary of Product Characteristics. Milton Keynes: Lundbeck Ltd; 2009. Available at: http://www​.medicines​.org.uk/EMC/medicine/21976/SPC.
  • MacDonald TM, McMahon AD, Reid IC, et al. Antidepressant drug use in primary care: a record linkage study in Tayside, Scotland. British Medical Journal. 1996;313:860–861. [PMC free article: PMC2359035] [PubMed: 8870575]
  • MacMillan HL, Patterson CJ, Wathen CN. Screening for depression in primary care: recommendation statement from the Canadian Task Force on Preventive Health Care. Canadian Medical Association Journal. 2005;172:33–35. [PMC free article: PMC543939] [PubMed: 15632399]
  • Maes M, Meltzer HY, Cosyns P, et al. An evaluation of basal hypothalamic-pituitary-thyroid axis function in depression: results of a large-scaled and controlled study. Psychoneuroendocrinology. 1993;18:607–620. [PubMed: 8127950]
  • Magnusson A, Partonen T. The diagnosis, symptomatology, and epidemiology of seasonal affective disorder. CNS Spectrums. 2005;10:625–634. [PubMed: 16041294]
  • The MaGPIe Research Group. The effectiveness of case-finding for mental health problems in primary care. British Journal of General Practice. 2005;55:665–669. [PMC free article: PMC1464072] [PubMed: 16176732]
  • The MaGPle Research Group. Do patients want to disclose psychological problems to GPs? Family Practice. 2005;22:631–637. [PubMed: 16055471]
  • Malhi GS, Parker GB, Greenwood J. Structural and functional models of depression: from sub-types to substrates. Acta Psychiatrica Scandinavica. 2005;111:94–105. [PubMed: 15667428]
  • Malitz S, Sackeim HA, Decina P, et al. The efficacy of electroconvulsive therapy: dose-response interactions with modality. Annals of the New York Academy of Sciences. 1986;462:56–64. [PubMed: 3458419]
  • Mallen C, Peat G. Screening older people with joint pain for depression in primary care. British Journal of General Practice. 2008;58:687–692.
  • Malt UF, Robak OH, Madsbu H-P, et al. The Norwegian naturalistic treatment study of depression in general practice (NORDEP). I: Randomised double-blind study. British Medical Journal. 1999;318:1180–1184. [PMC free article: PMC34546] [PubMed: 10221945]
  • Mann AH, Blizard R, Murray J, et al. An evaluation of practice nurses working with general practitioners to treat people with depression. British Journal of General Practice. 1998;48:875–879. [PMC free article: PMC1409896] [PubMed: 9604408]
  • Mann T. Clinical Guidelines: Using Clinical Guidelines to Improve Patient Care Within the NHS. London: NHS Executive; 1996.
  • Markowitz JS, DeVane CL, Liston HL, et al. An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. International Clinical Psychopharmacology. 2000;15:329–333. [PubMed: 11110008]
  • Marks IM, Mataix-Cols D, Kenwright M, et al. Pragmatic evaluation of computer-aided self-help for anxiety and depression. British Journal of Psychiatry. 2003;183:57–65. [PubMed: 12835245]
  • Marmor J. The future of psychoanalytic therapy. American Journal of Psychiatry. 1973;130:1197–1202. [PubMed: 4746027]
  • Marmor J. Academic lecture: the nature of the psychotherapeutic process revisisted. Canadian Psychiatric Association Journal. 1975;20:557–565. [PubMed: 1230301]
  • Marriott M, Kellett S. Evaluating a cognitive analytic therapy service: practice-based outcomes and comparisons with person-centred and cognitive-behavioural therapies. Psychology and Psychotherapy. 2009;82:57–72. [PubMed: 18759998]
  • Marshall M, Crowther R, Almaraz-Serrano AM, et al. Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care. Health Technology Assessment. 2001;5:1–75. [PubMed: 11532238]
  • Marshall M, Crowther R, Almaraz-Serrano AM, et al. Day hospital versus outpatient care for psychiatric disorders (Cochrane Review), Cochrane Library. 3. Oxford: Update Software; 2003.
  • Marteau TM. Psychological costs of screening. British Medical Journal. 1989;299:527. [PMC free article: PMC1837372] [PubMed: 2507059]
  • Martenyi F, Dossenbach M, Mraz K, et al. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. European Neuropsychopharmacology. 2001;11:227–232. [PubMed: 11418283]
  • Martin DJ, Garske JP, Davis MK. Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. Journal of Consulting and Clinical Psychology. 2000;68:438–450. [PubMed: 10883561]
  • Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. British Medical Journal. 2005;330:389–395. [PMC free article: PMC549107] [PubMed: 15718538]
  • May CM, Allison G, Chapple A, et al. Framing the doctor-patient relationship in chronic illness: a comparative study of general practitioners’ accounts. Sociology of Health and Illness. 2004;26:135–158. [PubMed: 15027982]
  • McCrone P, Chisholm D, Knapp M, et al. (the INCAT Study Group). Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy. European Journal of Neurology. 2003;10:687–694. [PubMed: 14641514]
  • McCrone P, Dhanasiri S, Patel A, et al. Paying the Price: The Cost of Mental Health Care in England to 2026. London: King’s Fund; 2008.
  • McGorry P, Jackson H. Recognition and Management of Early Psychosis: A Preventative Approach. Cambridge: Cambridge University Press; 1999.
  • McGrath PJ, Blood DK, Stewart JW, et al. A comparative study of the electrocardiographic effects of phenelzine, tricyclic antidepressants, mianserin and placebo. Journal of Clinical Psychopharmacology. 1987;7:335–339. [PubMed: 3680604]
  • McGrath PJ, Stewart JW, Harrison W, et al. Treatment of refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacology Bulletin. 1987;23:169–172. [PubMed: 3602314]
  • McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. American Journal of Psychiatry. 1993;150:118–123. [PubMed: 8417553]
  • Mead GE, Morley W, Campbell P, et al. Exercise for depression. Cochrane Database of Systematic Reviews. 2008;(4):CD004366. [PubMed: 18843656]
  • Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. British Journal of Clinical Pharmacology. 2001;52:179–184. [PMC free article: PMC2014522] [PubMed: 11488775]
  • Meijer WEE, Bouvy ML, Heerdink ER, et al. Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors. British Journal of Psychiatry. 2001;179:519–522. [PubMed: 11731355]
  • Melander H, Ahlqvist-Rastad J, Meijer G, et al. Evidence-based medicine –selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. British Medical Journal. 2003;326:1171–1173. [PMC free article: PMC156459] [PubMed: 12775615]
  • Meltzer H, Bebbington P, Brugha T, et al. The reluctance to seek treatment for neurotic disorders. Journal of Mental Health. 2000;9:319–327.
  • Merriman SH. Monoamine oxidase drugs and diet. Journal of Human Nutrition and Dietetics. 1999;12:21–28.
  • MHRA. Report of the CSM Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants. 2004. Available at: http://www​.mhra.gov.uk​/home/groups/pl-p/documents​/drugsafetymessage/con019472​.pdf.
  • MHRA. Venlafaxine (Efexor) – summary of basis for regulatory position. 2006. Available at: http://www​.mhra.gov.uk​/home/idcplg?IdcService​=GET_FILE&dDocName​=CON2023840&RevisionSelectionMethod​=LatestReleased.
  • MHRA. Updated prescribing advice for venlafaxine (Efexor/Efexor XL). 2006. [accessed May 2009]. Available at http://www​.mhra.gov.uk/
  • Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. British Journal of Psychiatry. 2000;176:363–368. [PubMed: 10827885]
  • Miller P, Chilvers C, Dewey M, et al. Counselling versus antidepressant therapy for the treatment of mild to moderate depression in primary care: economic analysis. International Journal of Technology Assessment in Health Care. 2003;19:80–90. [PubMed: 12701941]
  • Mills M, Pound A. Mechanisms of change: the Newpin Project. Mrace Bulletin. 1996;2:3–7.
  • Mindham RH. Tricyclic antidepressants, Drugs in Psychiatric Practice. Tyrer P, editor. Cambridge: Cambridge University Press; 1982.
  • Mitchell AJ, Subramaniam H. Prognosis of depression in old age compared to middle age: a systematic review of comparative studies. American Journal of Psychiatry. 2005;162:1588–1601. [PubMed: 16135616]
  • Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009;374:609–619. [PubMed: 19640579]
  • Mitchell PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety. 1997;17:390–406. [PubMed: 9429838]
  • Möller HJ, Baldwin DS, Goodwin G, et al. Do SSRIs or antidepressants in general increase suicidality? WPA Section on pharmacopsychiatry: consensus statement. European Archives of Psychiatry and Clinical Neuroscience. 2008;258:3–23. [PubMed: 18668279]
  • Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression, Cochrane Library. 4. Oxford: Update Software; 2001.
  • Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. International Clinical Psychopharmacology. 2004;19:271–280. [PubMed: 15289700]
  • Moore R, Garland A. Cognitive Therapy for Chronic and Persistent Depression. Chichester: Wiley; 2003.
  • Morgan O, Griffiths C, Baker A, et al. Fatal toxicity of antidepressants in England and Wales, 1993–2003. Health Statistics Quarterly. 2004;23:18–24. [PubMed: 15704381]
  • Mork A, Kreilgaard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology. 2003;45:167–173. [PubMed: 12842122]
  • Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370:851–858. [PubMed: 17826170]
  • Mucci M. Reboxetine: a review of antidepressant tolerability. Journal of Psychopharmacology. 1997;11(Suppl 4):S33–37. [PubMed: 9438231]
  • Murphy GE, Simons AD, Wetzel RD, et al. Cognitive therapy and pharmacotherapy singly and together in the treatment of depression. Archives of General Psychiatry. 1984;41:33–41. [PubMed: 6691783]
  • Murray CJL, Lopez AD, editors. The Global Burden of Disease A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge, Massachussetts: Harvard University Press; 1997.
  • Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349:1436–1442. [PubMed: 9164317]
  • Murray CJL, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bulletin of the World Health Organization. 1994;72:495–509. [PMC free article: PMC2486716] [PubMed: 8062404]
  • Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Archives of General Psychiatry. 1998;55:580–592. [PubMed: 9672048]
  • Mynors-Wallis LM, Gath DH, Baker F. Randomised controlled trial of problem-solving treatment, antidepressant medication, and combined treatment for major depression in primary care. British Medical Journal. 2000;320:26–30. [PMC free article: PMC27250] [PubMed: 10617523]
  • National Center for Education Statistics. Adult Literacy in America: A First Look at the Results of the National Adult Literacy Survey. US Department of Education; 1997.
  • NCCMH. Depression: Management of Depression in Primary and Secondary Care. Leicester & London: British Psychological Society and the Royal College of Psychiatrists; 2004.
  • NCCMH. Depression in Adults with a Chronic Physical Health Problem: Treatment and Management. Leicester & London: British Psychological Society and the Royal College of Psychiatrists; 2010.
  • Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biological Psychiatry. 2008;63:424–434. [PubMed: 17888885]
  • Neumeyer-Gromen A, Lampert T, Stark K, et al. Disease management programs for depression: a systematic review and meta-analysis of randomized controlled trials. Medical Care. 2004;42:1211–1221. [PubMed: 15550801]
  • Nezu AM. A problem-solving formulation of depression: a literature review and proposal of a pluralistic model. Clinical Psychology Review. 1987;7:121–144.
  • Nezu AM, Nezu CM, Perri MG. Problem-Solving Therapy for Depression: Theory Research and Clinical Guidelines. New York: Wiley; 1989.
  • NHS, Business Services Authority, Prescription Pricing Division. Electronic Drug Tariff for England and Wales, May 2009, Compiled on behalf of the Department of Health. 2009. [accessed 23 May 2009]. Available at: http://www​.ppa.org.uk​/edt/May_2009/mindex.htm.
  • NICE. Guidance on the Use of Computerised Cognitive Behavioural Therapy for Anxiety and Depression, Technology Appraisal 51. London: NICE; 2002.
  • NICE. Guidance on the Use of Electroconvulsive Therapy, Technology Appraisal 59. London: NICE; 2003.
  • NICE. Depression: Management of Depression in Primary and Secondary Care, Clinical Guideline 23. London: NICE; 2004.
  • NICE. Anxiety: Management of Anxiety (Panic Disorder, with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care, Clinical Guideline 22. London: NICE; 2004. [PubMed: 20945576]
  • NICE. Vagus Nerve Stimulation for Refractory Depression in Children, Interventional Procedures Guidance 50. London: NICE; 2004.
  • NICE. Depression in Children and Young People: Identification and Management in Primary, Community and Secondary Care, Clinical Guideline 28. London: NICE; 2005. [PubMed: 26459492]
  • NICE. Computerised Cognitive Behaviour Therapy for the Treatment of Depression and Anxiety, NICE Technology Appraisal 97. Review of Technology Appraisal 51. London: NICE; 2006.
  • NICE. Dementia: Supporting People with Dementia and their Carers in Health and Social Care, Clinical Guideline 42. London: NICE & SCIE; 2006.
  • NICE. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary care, NICE Clinical Guideline 38. London: NICE; 2006. [PubMed: 21796830]
  • NICE. Depression: Management of Depression in Primary and Secondary Care, Clinical Guideline 23 (amended). London: NICE; 2007.
  • NICE. The Guideline Development Process – An Overview for Stakeholders, the Public and the NHS. 3. London: NICE; 2007.
  • NICE. The Guidelines Manual. London: NICE; 2007.
  • NICE. Transcranial Magnetic Stimulation for Severe Depression, Interventional Procedure Guidance 242. London: NICE; 2007.
  • NICE. Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance, Clinical Guideline 45. London: NICE; 2007.
  • NICE. Guide to the Methods of Technology Appraisal. London: NICE; 2008.
  • NICE. Social Value Judgements. Principles for the Development of NICE guidance. 2. London: NICE; 2008. [PubMed: 27905706]
  • NICE. The Guidelines Manual. London: NICE; 2009.
  • NICE. Medicines Adherence: Involving Patients in Decisions about Prescribed Medicines and Supporting Adherence, Clinical Guideline 76. London: NICE; 2009. [PubMed: 21834197]
  • NICE. Depression in Adults with a Chronic Physical Health Problem: Treatment and Management, Clinical Guideline 91. London: NICE; 2009.
  • Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146,538 participants in 54 observational studies. European Heart Journal. 2006;27:2763–2774. [PubMed: 17082208]
  • Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. Journal of Clinical Psychiatry. 1990;51:39–47. [PubMed: 2112132]
  • Nierenberg AA, McLean NE, Alpert JE, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. American Journal of Psychiatry. 1995;152:1500–1503. [PubMed: 7573590]
  • Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onsent of antidepressant response with fluoxetine treatment. American Journal of Psychiatry. 2000;157:1423–1428. [PubMed: 10964858]
  • Nolan P, Murray E, Dallender J. Practice nurses’ perceptions of services for clients with psychological problems in primary care. International Journal of Nursing Studies. 1999;36:97–104. [PubMed: 10376219]
  • Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. II: MAO inhibitors in depression resistant to cyclic antidepressants – two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatrica Scandinavica. 1988;78:676–683. [PubMed: 3146891]
  • Nolen WA, Hoencampe E, Halmans PMJ. Classical and selective monoamine oxidase inhibitors in refractory major depression, Refractory Depression: Current Strategies and Future Directions. Nolen WA, Zohar SP, Roose SP, Amsterdam JD, editors. Chichester: Wiley; 1994. pp. 59–68.
  • Normann C, Hummel B, Schärer LO, et al. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. Journal of Clinical Psychiatry. 2002;63:337–344. [PubMed: 12000208]
  • Nuechterlein KH, Dawson ME. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophrenia Bulletin. 1984;10:300–312. [PubMed: 6729414]
  • Nutt DJ. Tolerability and safety aspects of mirtazapine. Human Psychopharmacology. 2002;17(Suppl 1):S37–41. [PubMed: 12404669]
  • Ofman JJ, Badamgarav E, Henning JM, et al. Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. American Journal of Medicine. 2004;117:182–192. [PubMed: 15300966]
  • Okiishi J, Lambert MJ, Nielsen SL, et al. Waiting for supershrink: an empirical analysis of therapist effects. Clinical Psychology and Psychotherapy. 2003;10:361–373.
  • Ormel J, Costa e Silva JA. The impact of psychopathology on disability and health perceptions, Mental Illness in General Health Care: an International Study. Üstün TB, Sartorius N, editors. Chichester: Wiley; 1995. pp. 335–346.
  • Ormel J, van den Brink W, Koeter MWJ, et al. Recognition, management and outcome of psychological disorders in primary care: a naturalistic follow-up study. Psychological Medicine. 1990;20:909–923. [PubMed: 2284397]
  • Ormel J, von Korff M, Oldehinkel T, et al. Onset of disability in depressed and non-depressed primary care patients. Psychological Medicine. 1999;29:847–853. [PubMed: 10473311]
  • Osgood-Hynes DJ, Greist DH, Marks IM, et al. Self-administered psychotherapy for depression using a telephone-accessed computer system plus booklets: an open US–UK study. Journal of Clinical Psychiatry. 1998;59:358–365. [PubMed: 9714264]
  • Ostler K, Thompson C, Kinmonth ALK, et al. Influence of socioeconomic deprivation on the prevalence and outcome of depression in primary care: the Hampshire Depression Project. British Journal of Psychiatry. 2001;178:12–17. [PubMed: 11136204]
  • Ostrom M, Eriksson A, Thorson J, et al. Fatal overdose with citalopram. Lancet. 1996;348:339–340. [PubMed: 8709713]
  • Palmer SC, Coyne JC. Screening for depression in medical care: pitfalls, alternatives, and revised priorities. Journal of Psychosomatic Research. 2003;54:279–287. [PubMed: 12670603]
  • Papakostas GI, Montgomery SA, Thase ME, et al. Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials. Journal of Clinical Psychiatry. 2007;68:1907–1912. [PubMed: 18162022]
  • Patten SB. Are the Brown and Harris ‘vulnerability factors’ risk factors for depression? Journal of Psychiatry and Neuroscience. 1991;16:267–271. [PMC free article: PMC1188364] [PubMed: 1797101]
  • Paykel ES, Freeling P, Hollyman JA. Are tricyclic antidepressants useful for mild depression? A placebo-controlled trial. Pharmacopsychiatry. 1988;21:15–18. [PubMed: 3283783]
  • Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychological Medicine. 1995;25:1171–1180. [PubMed: 8637947]
  • Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy. Archives of General Psychiatry. 1999;56:829–835. [PubMed: 12884889]
  • Peckham CS, Dezateux C. Issues underlying the evaluation of screening programmes. British Medical Bulletin. 1998;54:767–778. [PubMed: 10367413]
  • Peet M, Tienari P, Jaskari MO. A comparison of the cardiac effects of mianserin and amitriptyline in man. Pharmakopsychiatrie Neuropsychopharmakologie. 1977;10:309–312. [PubMed: 360245]
  • Penttinen J, Valonen P. Use of psychotropic drugs and risk of myocardial infarction: a case-control study in Finnish farmers. International Journal of Epidemiology. 1996;25:760–762. [PubMed: 8921453]
  • Personne M, Sjoberg G, Persson H. Citalopram overdose: review of cases treated in Swedish hospitals. Journal of Toxicology and Clinical Toxicology. 1997;35:237–240. [PubMed: 9140316]
  • Personne M, Sjoberg G, Persson H. Citalopram toxicity. Lancet. 1997;350:518–519. [PubMed: 9274602]
  • Peselow ED, Filippi AM, Goodnick P, et al. The short- and long-term efficacy of paroxetine HCl: A. Data from a six-week double-blind parallel design trial vs. imipramine and placebo. Psychopharmacology Bulletin. 1989;25:267–271. [PubMed: 2532373]
  • Peveler R, George C, Kinmonth AL, et al. Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial. British Medical Journal. 1999;319:612–615. [PMC free article: PMC28214] [PubMed: 10473477]
  • Peveler R, Kendrick T, Buxton M, et al. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technology Assessment. 2005;9:1–134. [PubMed: 15876362]
  • Piaggio G, Elbourne DR, Altman DG, et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. Journal of the American Medical Association. 2006;295:1152–1160. [PubMed: 16522836]
  • Pignone MP, Gaynes BN, Rushton JL, et al. Screening for depression in adults: a summary of the evidence for the US Preventive Services Task Force. Annals of Internal Medicine. 2002;136:765–776. [PubMed: 12020146]
  • Pilgrim D, Bentall R. The medicalisation of misery: a critical realist analysis of the concept of depression. Journal of Mental Health. 1999;8:261–274.
  • Pilgrim D, Dowrick C. From a diagnostic-therapeutic to a social-existential response to ‘depression’ Journal of Public Mental Health. 2006;5:6–12.
  • Pilling S. History, context, process, and rationale for the development of clinical guidelines. Psychology and Psychotherapy. 2008;81:331–350. [PubMed: 18983729]
  • Pilling SA, Cape J, Liebowitz JA, et al. Enhanced care for depression: a study in primary care (unpublished) 2010
  • Plummer S, Ritter SAH, Leach RE, et al. A controlled comparison of the ability of practice nurses to detect psychological distress in patients who attend their clinics. Journal of Psychiatric and Mental Health Nursing. 1997;4:221–223. [PubMed: 9325803]
  • Pollock K, Grime J. Patients’ perceptions of entitlement to time in general practice consultations for depression: a qualitative study. British Medical Journal. 2002;325:687–690. [PMC free article: PMC126657] [PubMed: 12351362]
  • Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. Journal of Clinical Psychopharmacology. 2000;20:137–140. [PubMed: 10770450]
  • Popay J, Kowarzik U, Mallinson S, et al. Social problems, primary care and pathways to at the individual level. Part I: the GP perspective help and support: addressing health inequalities. Journal of Epidemiology and Community Health. 2007;61:966–971. [PMC free article: PMC2465599] [PubMed: 17933954]
  • Porter RJ, Douglas K, Knight RG. Monitoring of cognitive effects during a course of electroconvulsive therapy: recommendations for clinical practice. Journal of ECT. 2008;24:25–34. [PubMed: 18379332]
  • Posternak MA, Miller I. Untreated short-term course of major depression: a meta-analysis of outcomes from studies using wait-list control groups. Journal of Affective Disorders. 2001;66:139–146. [PubMed: 11578666]
  • Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? Journal of Clinical Psychiatry. 2005;66:148–158. [PubMed: 15704999]
  • Posternak MA, Zimmerman M. Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials. British Journal of Psychiatry. 2007;190:287–292. [PubMed: 17401033]
  • Posternak MA, Solomon DA, Leon AC, et al. The naturalistic course of unipolar major depression in the absence of somatic therapy. Journal of Nervous and Mental Disorders. 2006;194:324–329. [PubMed: 16699380]
  • Prasher V. Presentation and management of depression in people with learning disability. Advances in Psychiatric Treatment. 1999;5:447–454.
  • Pratt LA, Ford DF, Crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation. 1996;94:3123–3129. [PubMed: 8989119]
  • Price LH, Carpenter LL, Rasmussen SA. Drug combination strategies, Treatment Resistant Mood Disorders. Amsterdam JD, Hornig M, Nierenberg AA, editors. Cambridge: Cambridge University Press; 2001. pp. 194–222.
  • Priest RG, Vize C, Roberts A, et al. Lay people’s attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its launch. British Medical Journal. 1996;313:858–859. [PMC free article: PMC2359082] [PubMed: 8870574]
  • Prins MA, Verhaak PFM, Bensing JM, et al. Health beliefs and perceived need for mental health care of anxiety and depression: the patients’ perspective explored. Clinical Psychology Review. 2008;28:1038–1058. [PubMed: 18420323]
  • Proudfoot J, Ryden C, Everitt B, et al. Clinical efficacy of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. British Journal of Psychiatry. 2004;185:46–54. [PubMed: 15231555]
  • Pyne J, Sieber W, David K, et al. Use of the quality of well-being self-administered version (QWB-SA) in assessing health-related quality of life in depressed patients. Journal of Affective Disorders. 2003;76:237–247. [PubMed: 12943954]
  • Quitkin FM, Rabkin JD, Markowitz JM, et al. Use of pattern analysis to identify true drug response. A replication. Archives of General Psychiatry. 1987;44:259–264. [PubMed: 3548638]
  • Quitkin FM, Harrison W, Stewart JW, et al. Response to phenelzine and imipramine in placebo non-responders with atypical depression. A new application of the crossover design. Archives of General Psychiatry. 1991;48:319–323. [PubMed: 2009033]
  • Quitkin FM, Stewart JW, McGrath PJ. Gender differences in treatment response. American Journal of Psychiatry. 2001;158:1531–1533. [PubMed: 11532756]
  • Quitkin FM, Petkova E, McGrath PJ, et al. When should a trial of fluoxetine for major depression be declared failed? American Journal of Psychiatry. 2003;160:734–740. [PubMed: 12668363]
  • Rabins P. Barriers to diagnosis and treatment of depression in elderly patients. American Journal of Geriatric Psychiatry. 1996;4:79–84.
  • Rabkin JG, Markowitz JS, Stewart JW, et al. How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Research. 1986;19:75–86. [PubMed: 3538107]
  • Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement. 1977;1:385–401.
  • Raine R, Lewis L, Sensky T, et al. Patient determinants of mental health interventions in primary care. British Journal of General Practice. 2000;50:620–625. [PMC free article: PMC1313771] [PubMed: 11042912]
  • Rait G, Burns A, Baldwin R, et al. Screening for depression in African-Caribbean elders. Family Practice. 1999;16:591–595. [PubMed: 10625132]
  • Ramachandani P, Stein A. The impact of parental psychiatric disorder on children. British Medical Journal. 2003;327:242–243. [PMC free article: PMC1126643] [PubMed: 12896914]
  • Ramana R, Paykel ES, Surtees PG, et al. Medication received by patients with depression following the acute episode: adequacy and relation to outcome. British Journal of Psychiatry. 1999;174:128–134. [PubMed: 10211166]
  • Rami L, Bernardo M, Boget T, et al. Cognitive status of psychiatric patients under maintenance electroconvulsive therapy: a one-year longitudinal study. Journal of Neuropsychiatry and Clinical Neuroscience. 2004;16:465–471. [PubMed: 15616173]
  • Rami-Gonzalez L, Salamero M, Boget T, et al. Pattern of cognitive dysfunction in depressive patients during maintenance electroconvulsive therapy. Psychological Medicine. 2003;33:345–350. [PubMed: 12622313]
  • Rapp SR, Davis KM. Geriatric depression: physicians’ knowledge, perceptions, and diagnostic practices. Gerontologist. 1989;29:252–257. [PubMed: 2753387]
  • Rasmussen SL, Overo KF, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. Journal of Clinical Psychopharmacology. 1999;19:407–415. [PubMed: 10505582]
  • Rawlins MD. De Testimonio. On the Evidence for Decisions about the Use of Therapeutic Interventions, The Harveian Oration of 2008. Delivered before the Fellows of The Royal College of Physicians of London on Thursday 16 October 2008. London: Royal College of Physicians; 2008. Available at: http://www​.rcplondon​.ac.uk/pubs/contents​/304df931-2ddc-4a54-894e-e0cdb03e84a5​.pdf.
  • Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355:1048–1052. [PubMed: 10744090]
  • Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and anti-depressant medications. Journal of Affective Disorders. 1998;48:25–36. [PubMed: 9495599]
  • Richards A, Barkham M, Cahill J, et al. PHASE: a randomised, controlled trial of supervised self-help cognitive behavioural therapy in primary care. British Journal of General Practice. 2003;53:764–770. [PMC free article: PMC1314708] [PubMed: 14601351]
  • Richards DA, Suckling R. Improving access to psychological therapy: the Doncaster demonstration site organisational model. Clinical Psychology Forum. 2008;181:9–16.
  • Richards D, Whyte M. Reach out: national programme student materials to support the delivery of training for practitioners delivering low intensity interventions. London: Rethink; 2008. Available at: http://www​.iapt.nhs.uk​/wp-content/uploads​/2008/07/0725_student-manual-18july.pdf.
  • Richards DA, Lovell K, Gilbody S, et al. Collaborative care for depression in UK primary care: a randomized comtrolled trial. Psychological Medicine. 2008;38:279–287. [PubMed: 17803837]
  • Richardson R, Richards DA, Barkham M. Self-help books for people with depression: a scoping review. Journal of Mental Health. 2008;17:543–552.
  • Ridge D, Ziebland S. ‘The old me could never have done that’: how people give meaning to recovery following depression. Qualitative Health Research. 2006;16:1038–1053. [PubMed: 16954524]
  • Rinaldi M, Perkins R, Glynn E, et al. Individual placement and support: from research to practice. Advances in Psychiatric Treatment. 2008;14:50–60.
  • Roberts D, Bernard M, Misca G, et al. Experiences of Children and Young People Caring for a Parent with a Mental Health Problem, Research Briefing No. 24. London: Social Care Institute for Excellence; 2008.
  • Robinson LA, Berman JS, Neimeyer RA. Psychotherapy for the treatment of depression: a comprehensive review of controlled outcome research. Psychological Bulletin. 1990;108:30–49. [PubMed: 2200072]
  • Rodin I, Thompson C. Seasonal affective disorder. Advances in Psychiatric Treatment. 1997;3:352–359.
  • Rogers A, Hassell K, Nicolaas G. Demanding Patients? Analysing the Use of Primary Care. Milton Keynes: Open University Press; 1999.
  • Rogers A, May C, Oliver D. Experiencing depression, experiencing the depressed: the separate worlds of patients and doctors. Journal of Mental Health. 2001;10:317–333.
  • Rogers CR. Client-Centered Therapy: Its Current Practice, Implications, and Theory. Oxford; Houghton Miffin: 1951.
  • Rogers CR. The necessary and sufficient conditions of therapeutic personality change. Journal of Consulting Psychology. 1957;21:95–103. [PubMed: 13416422]
  • Rogers CR. Rogers, Kohut and Erikson. A personal perspective on some similarities and differences. Person-Centered Review. 1986;1:125–140.
  • Romeo R, Patel A, Knapp M, et al. The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care. International Clinical Psychopharmacology. 2004;19:125–134. [PubMed: 15107654]
  • Roose SP. Depression, anxiety, and the cardiovascular system: the psychiatrist’s perspective. Journal of Clinical Psychiatry. 2001;62(Suppl 8):19–22. [PubMed: 12108817]
  • Roose SP. Treatment of depression in patients with heart disease. Biological Psychiatry. 2003;54:262–268. [PubMed: 12893102]
  • Roose SP, Glassman AH. Cardiovascular effects of tricyclic antidepressants in depressed patients with and without heart disease. Journal of Clinical Psychiatry Monograph. 1989;7:1–19.
  • Roose SP, Glassman AH, Giardina EGV, et al. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Archives of General Psychiatry. 1987;44:273–275. [PubMed: 3827520]
  • Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine to nortriptyline in depressed patients with ischemic heart disease. Journal of the American Medical Association. 1998;279:287–291. [PubMed: 9450712]
  • Roose SP, Glassman AH, Attia E, et al. Cardiovascular effects of fluoxetine in depressed patients with heart disease. American Journal of Psychiatry. 1998;155:660–665. [PubMed: 9585718]
  • Rose D, Fleischmann P, Wykes T, et al. Patients’ perspectives on electroconvulsive therapy: systematic review. British Medical Journal. 2003;326:1363. [PMC free article: PMC162130] [PubMed: 12816822]
  • Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomised clinical trial. Biological Psychiatry. 1998;44:77–87. [PubMed: 9646889]
  • Rosenthal NE, Sack DA, Gillin JC, et al. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Archives of General Psychiatry. 1984;41:72–80. [PubMed: 6581756]
  • Ross DC, Quitkin FM, Klein DF. A typological model for estimation of drug and placebo effects in depression. Journal of Clinical Psychopharmacology. 2002;22:414–418. [PubMed: 12172342]
  • Rost K, Humphrey J, Kelleher K. Physician management preferences and barriers to care for rural patients with depression. Archives of Family Medicine. 1994;3:409–414. [PubMed: 8032501]
  • Rost K, Williams C, Wherry J, et al. The process and outcomes of care for major depression in rural family practice settings. Journal of Rural Health. 1995;11:114–121. [PubMed: 10143272]
  • Rost K, Nutting PA, Smith J, et al. Designing and implementing a primary care intervention trial to improve the quality and outcome of care for major depression. General Hospital Psychiatry. 2000;22:66–77. [PubMed: 10822094]
  • Rost K, Nutting P, Smith J, et al. Improving depression outcomes in community primary care practices: a randomized trial of the QuEST intervention. Journal of General Internal Medicine. 2001;16:143–149. [PMC free article: PMC1495192] [PubMed: 11318908]
  • Roter DL, Hall JA, Kern DE, et al. Improving physicians’ interviewing skills and reducing patients’ emotional distress. A randomised clinical trial. Archives of Internal Medicine. 1995;155:1877–1884. [PubMed: 7677554]
  • Roth A, Fonagy P. What Works for Whom: A Critical Review of Psychotherapy Research. New York: Guilford; 1996.
  • Roth AD, Pilling S. The impact of adherence and competence on outcome in CBT and psychological therapies. 2009 In preparation.
  • Roth AJ, Kornblith AB, Batel-Copel L, et al. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer. 1998;82:1904–1908. [PubMed: 9587123]
  • Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biological Psychiatry. 2003;53:680–690. [PubMed: 12706954]
  • Rounsaville BJ, Carroll KM, Onken LS. NIDA’s stage model of behavioral therapies research: getting started and moving on from Stage I. Clinical Psychology: Science and Practice. 2001;8:133–142.
  • Rowe D. Depression: the Way out of Your Prison. London: Routledge & Kegan Paul; 1983.
  • Rowe SK, Rapaport MH. Classification and treatment of sub-threshold depression. Current Opinion in Psychiatry. 2006;19:9–13. [PubMed: 16612172]
  • Royal College of Psychiatrists. Benzodiazepines: Risks, Benefits or Dependence A Re-evaluation, Council Report CR59. London: Royal College of Psychiatrists; 1997.
  • Royal College of Psychiatrists. The ECT Handbook Second Edition The Third Report of the Royal College of Psychiatrists’ Special Committee on ECT. In: Scott AIF, editor. Council Report CR128. London: Royal College of Psychiatrists; 2005.
  • Royal College of Psychiatrists. Mental Health and Work. London: Royal College of Psychiatrists; 2008.
  • Rush AJ, Beck AT, Kovacs M, et al. Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients. Cognitive Therapy and Research. 1977;1:17–37.
  • Rush AJ, Kovacs M, Beck AT, et al. Differential effects of cognitive therapy and pharmacotherapy on depressive symptoms. Journal of Affective Disorders. 1981;3:221–229. [PubMed: 6456289]
  • Rush AJ, Trivedi M, Fava M. STAR*D treatment trial for depression. American Journal of Psychiatry. 2003;160:237. [PubMed: 12562566]
  • Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry. 2006;163:1905–1917. [PubMed: 17074942]
  • Russell JC, Rasmussen KG, O’Connor MK, et al. Long-term maintenance ECT: a retrospective review of efficacy and cognitive outcome. Journal of ECT. 2003;19:4–9. [PubMed: 12621270]
  • Sackeim HA, Decina P, Kanzler M, et al. Effects of electrode placement on the efficacy of titrated, low-does ECT. American Journal of Psychiatry. 1987;144:1449–1455. [PubMed: 3314538]
  • Sainsbury Centre for Mental Health. Mental Health at Work: Developing the Business Case, Policy Paper 8. London: Sainsbury Centre for Mental Health; 2007.
  • Salkovskis PM. Demonstrating specific effects in cognitive and behavioural therapy, Research Foundations for Psychotherapy Research. Aveline M, Shapiro DA, editors. Chichester: Wiley and Sons; 1995. pp. 191–228.
  • Santos MA, Rocha FL, Hara C, et al. Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. Journal of Clinical Psychiatry. 2008;10:187–190. [PMC free article: PMC2446484] [PubMed: 18615166]
  • Sapin C, Fantino B, Nowicki ML, et al. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health and Quality of Life Outcomes. 2004;2:20. [PMC free article: PMC416488] [PubMed: 15128456]
  • Sartorius N. The economic and social burden of depression. Journal of Clinical Psychiatry. 2001;62(Suppl 15):8–11. [PubMed: 11444765]
  • Sartorius N. Eines der letzen Hindernisse einer verbesserten psychiatrischen Versorgung: das Stigma psychisher Erkrankung [One of the last obstacles to better mental health care: the stigma of mental illness] Neuropsychiatrie. 2002;16:5–10.
  • Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894–1898. [PubMed: 11602490]
  • Saver BG, Van-Nguyen V, Keppel G, et al. A qualitative study of depression in primary care: missed opportunities for diagnosis and education. The Journal of the American Board of Family Medicine. 2007;20:28–35. [PubMed: 17204732]
  • Schaffer A, Levitt AJ, Hershkop SK, et al. Utility scores of symptom profiles in major depression. Psychiatry Research. 2002;110:189–197. [PubMed: 12057830]
  • Schindler F, Anghelescu IG. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. International Clinical Psychopharmacology. 2007;22:179–182. [PubMed: 17414745]
  • Schneider LS, Small GW. The increasing power of placebos in trials of antidepressants. Journal of the American Medical Association. 2002;288:450. [PubMed: 12132971]
  • Schweizer E, Rickels K, Amsterdam JD, et al. What constitutes an adequate antidepressant trial for fluoxetine? Journal of Clinical Psychiatry. 1990;51:8–11. [PubMed: 2403998]
  • Schweizer E, Rynn M, Mandos LA, et al. The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial. International Clinical Psychopharmacology. 2001;16:137–143. [PubMed: 11354235]
  • Scott C, Tacchi MJ, Jones R, et al. Acute and one-year outcome of a randomised controlled trial of brief cognitive therapy for major depressive disorder in primary care. British Journal of Psychiatry. 1997;171:131–134. [PubMed: 9337947]
  • Scott J, Teasdale JD, Paykel ES, et al. Effects of cognitive therapy on psychological symptoms and social functioning in residual depression. British Journal of Psychiatry. 2000;177:440–446. [PubMed: 11059998]
  • Scott J, Palmer S, Paykel E, et al. Use of cognitive therapy for relapse prevention in chronic depression. Cost-effectiveness study. British Journal of Psychiatry. 2003;182:221–227. [PubMed: 12611785]
  • Segal Z, Teasdale J, Williams M. Mindfulness-Based Cognitive Therapy for Depression. New York: Guilford Press; 2002.
  • Selmi PM, Klein MH, Greist JH, et al. Computer-administered cognitive-behavioural therapy for depression. American Journal of Psychiatry. 1990;147:51–56. [PubMed: 2403473]
  • Serby M, Yu M. Overview: depression in the elderly. Mount Sinai Journal of Medicine. 2003;70:38–44. [PubMed: 12516008]
  • Shah R, Uren Z, Baker A, et al. Trends in deaths from drug overdose and poisoning in England and Wales 1993–1998. Journal of Public Health Medicine. 2001;23:242–246. [PubMed: 11585199]
  • Shaw CM, Creed F, Tomenson B, et al. Prevalence of anxiety and depressive illness and help seeking behaviour in African Caribbeans and white Europeans: two phase general population survey. British Medical Journal. 1999;318:302–306. [PMC free article: PMC27715] [PubMed: 9924059]
  • Simon G. Collaborative care for depression: is effective in older people, as IMPACT trial shows. British Medical Journal. 2006;332:249–250. [PMC free article: PMC1360381] [PubMed: 16455698]
  • Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. American Journal of Psychiatry. 2007;164:1029–1034. [PubMed: 17606654]
  • Simon GE, von Korff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. Journal of the American Medical Association. 1996;275:1897–1902. [PubMed: 8648870]
  • Simon GE, Goldberg DP, von Korff M, et al. Understanding cross-national differences in depression prevalence. Psychological Medicine. 2002;32:585–594. [PubMed: 12102373]
  • Simon GE, Ludman EJ, Tutty S, et al. Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment: a randomized trial. Journal of the American Medical Association. 2004;292:935–942. [PubMed: 15328325]
  • Simon GE, Savarino J, Operskalski B, et al. Suicide risk during antidepressant treatment. American Journal of Psychiatry. 2006;163:41–47. [PubMed: 16390887]
  • Simpson S, Corney R, Fitzgerald P, et al. A randomized controlled trial to evaluate the effectiveness and cost-effectiveness of psychodynamic counselling for general practice patients with chronic depression. Psychological Medicine. 2003;33:229–239. [PubMed: 12622302]
  • Singh G, Verma HC, Verma RS, et al. A new depressive inventory. Indian Journal of Psychiatry. 1974;161:83–188.
  • Singleton N, Bumpstead R, O’Brien M, et al. Psychiatric Morbidity Among Adults Living in Private Households, 2000. London: The Stationery Office; 2001.
  • Sir A, D’Souza RF, Uguz S, et al. Randomised trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. Journal of Clinical Psychiatry. 2005;66:1312–1320. [PubMed: 16259546]
  • Skodol AE, Oldman JM, Gallaher PE. Axis II comorbidity of substance use disorders among patients referred for treatment of personality disorders. American Journal of Psychiatry. 1999;156:733–738. [PubMed: 10327906]
  • Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. British Journal of Psychiatry. 2002;180:396–404. [PubMed: 11983635]
  • Sneed JR, Rutherford BR, Rindskopf D, et al. Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. American Journal of Geriatric Psychiatry. 2008;16:65–73. [PubMed: 17998306]
  • Sobin C, Sackeim HA, Prudic J, et al. Predictors of retrograde amnesia following ECT. American Journal of Psychiatry. 1995;152:995–1001. [PubMed: 7793470]
  • Solomon DA, Keller MB, Leon AC, et al. Recovery from major depression. A 10-year prospective follow-up across multiple episodes. Archives of General Psychiatry. 1997;54:1001–1006. [PubMed: 9366656]
  • Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. American Journal of Psychiatry. 2000;157:229–233. [PubMed: 10671391]
  • Sotsky SM, Glass DR, Shea MT, et al. Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Programme. American Journal of Psychiatry. 1991;148:997–1008. [PubMed: 1853989]
  • Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. Journal of the American Medical Assocaition. 1994;2(72):1749–1756. [PubMed: 7966923]
  • Spitzer RL, Kroenke K, Williams JB, et al. Validation and utility of a self-report version of the PRIME-MD: the PHQ primary care study. Journal of the American Medical Association. 1999;282:1737–1744. [PubMed: 10568646]
  • Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. European Neuropsychopharmacology. 1993;3:127–135. [PubMed: 8364348]
  • Steiner M, Radwan M, Elizur A, et al. Failure of L-triiodothyronine (T3) to potentiate tricyclic antidepressant response. Current Therapeutic Research, Clinical and Experimental. 1978;23:655–659.
  • Stewart JW, Quitkin FM, Liebowitz MR, et al. Efficacy of desipramine in depressed outpatients. Response according to research diagnosis criteria diagnoses and severity of illness. Archives of General Psychiatry. 1983;40:202–207. [PubMed: 6337580]
  • Stiles WB, Barkham M, Twigg E, et al. Effectiveness of cognitive-behavioural, person-centred and psychodynamic therapies as practised in UK National Health Service settings. Psychological Medicine. 2006;36:555–566. [PubMed: 16476185]
  • Stiles WB, Barkham M, Mellor-Clark J, et al. Effectiveness of cognitive-behavioural, person-centred and psychodynamic therapies in UK primary-care routine practice: replication in a larger sample. Psychological Medicine. 2008;38:677–688. [PubMed: 17825124]
  • Stirman SW, Derubeis RJ, Crits-Christoph P, et al. Can the randomized controlled trial literature generalize to nonrandomized patients? Journal of Consulting and Clinical Psychology. 2005;73:127–135. [PubMed: 15709839]
  • Strik JJ, Honig A, Lousberg R, et al. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosomatic Medicine. 2000;62:783–789. [PubMed: 11138997]
  • Sullivan MD, Katon WJ, Russo JE, et al. Patients’ beliefs predict responses to paroxetine among primary care patients with dysthymia and minor depression. The Journal of the American Board of Family Practice. 2003;16:22–31. [PubMed: 12583647]
  • Swindle RW, Rao JK, Helmy A, et al. Integrating clinical nurse specialists into the treatment of primary care patients with depression. International Journal of Psychiatry in Medicine. 2003;33:17–37. [PubMed: 12906341]
  • Szegedi A, Muller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. Journal of Clinical Psychiatry. 2003;64:413–420. [PubMed: 12716243]
  • Szegedi A, Jansen WT, van Willigenburg APP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. Journal of Clinical Psychiatry. 2009;70:344–353. [PubMed: 19254516]
  • Tamminga CA, Nemeroff CB, Blakely RD, et al. Developing novel treatments for mood disorders: accelerating discovery. Biological Psychiatry. 2002;52:589–609. [PubMed: 12361670]
  • Taylor D. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses. British Journal of Psychiatry. 1995;167:575–580. [PubMed: 8564311]
  • Taylor D, Stewart S, Connolly A. Antidepressant withdrawal symptoms: telephone calls to a national medication helpline. Journal of Affective Disorders. 2006;95:129–133. [PubMed: 16797080]
  • Taylor D, Paton C, Kerwin R. The Maudsley Prescribing Guidelines. 9. London: Informa Healthcare; 2007.
  • Thase ME. Studying new antidepressants: if there were a light at the end of the tunnel, could we see it? Journal of Clinical Psychiatry. 2002;63(Suppl 2):24–27. [PubMed: 15453011]
  • Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant non-responders. Journal of Clinical Psychiatry. 1997;58(Suppl 13):23–29. [PubMed: 9402916]
  • Thase ME, Kupfer DJ, Jarrett DB. Treatment of imipramine-resistant recurrent depression. I: An open clinical trial of adjunctive L-triiodothyronine. Journal of Clinical Psychiatry. 1989;50:385–388. [PubMed: 2676995]
  • Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine-resistant recurrent depression. IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. American Journal of Psychiatry. 1992;149:195–198. [PubMed: 1734739]
  • Thiels C, Schmidt U, Treasure J, et al. Guided self change for bulimia nervosa incorporating use of a self-care manual. American Journal of Psychiatry. 1998;155:947–953. [PubMed: 9659862]
  • Thiels C, Linden M, Grieger F, et al. Gender differences in routine treatment of depressed outpatients with the selective serotonin reuptake inhibitor sertraline. International Clinical Psychopharmacology. 2005;20:1–7. [PubMed: 15602108]
  • Thomas CM, Morris S. Cost of depression among adults in England in 2000. British Journal of Psychiatry. 2003;183:514–519. [PubMed: 14645022]
  • Thompson C, Thompson CM. The prescribing of antidepressants in general practice. II: A placebo-controlled trial of low-dose dothiepin. Human Psychopharmacology. 1989;4:191–204.
  • Thompson C, Kinmonth AL, Stevens L, et al. Effects of good practice guidelines and practice-based education on the detection and treatment of depression in primary care. Hampshire Depression Project randomised controlled trial. Lancet. 2000;355:185–191. [PubMed: 10675118]
  • Thompson C, Ostler K, Peveler RC, et al. Dimensional perspective on the recognition of depressive symptoms in primary care: the Hampshire Depression Project 3. British Journal of Psychiatry. 2001;179:317–323. [PubMed: 11581111]
  • Thompson C, Thompson S, Smith R. Prevalence of seasonal affective disorder in primary care: a comparison of the seasonal health questionnaire and the seasonal pattern assessment questionnaire. Journal of Affective Disorders. 2004;78:219–226. [PubMed: 15013246]
  • Thompson LW, Gallagher D, Breckenridge JS. Comparative effectiveness of psychotherapies for depressed elders. Journal of Consulting and Clinical Psychology. 1987;55:385–390. [PubMed: 3597953]
  • Thoren P, Floras JS, Hoffmann P, et al. Endorphins and exercise: physiological mechanisms and clinical implications. Medical Science, Sports and Exercise. 1990;22:417–428. [PubMed: 2205777]
  • Thorogood M, Cowen P, Mann J, et al. Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet. 1992;340:1067–1068. [PubMed: 1357456]
  • Tiemens B, Ormel J, Jenner JA, et al. Training primary-care physicians to recognise, diagnose and manage depression: does it improve patient outcomes? Psychological Medicine. 1999;29:833–845. [PubMed: 10473310]
  • Tint A, Haddad PM, Anderson IM. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomized study. Journal of Psychopharmacology. 2008;22:330–332. [PubMed: 18515448]
  • Treasure J, Schmidt U, Troop N, et al. Sequential treatment for bulimia nervosa incorporating a self-care manual. British Journal of Psychiatry. 1996;168:94–98. [PubMed: 8770436]
  • Trepka C, Rees A, Shapiro DA, et al. Therapist competence and outcome of cognitive therapy for depression. Cognitive Therapy and Research. 2004;28:143–157.
  • Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry. 2006;163:28–40. [PubMed: 16390886]
  • Truax CB, Carkhuff RR. Toward Effective Counseling and Psychotherapy: Training and Practice. Chicago, Illinois: Aldine; 1967.
  • Unutzer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: a randomised controlled trial. Journal of the American Medical Association. 2002;288:2836–2845. [PubMed: 12472325]
  • Üstün TB, Sartorius N, editors. Mental Illness in General Health Care: An International Study. Chichester: Wiley; 1995.
  • Van HL, Schoevers RA, Dekker J. Predicting the outcome of antidepressants and psychotherapy for depression: a qualitative, systematic review. Harvard Review of Psychiatry. 2008;16:225–234. [PubMed: 18661365]
  • Van der Burght M. Citalopram Product Monography. Copenhagen, Denmark: H Lundbeck A/S; 1994.
  • Van Os TW, van den Brink RH, Tiemens BG, et al. Are effects of depression management training for general practitioners on patient outcomes mediated by improvements in the process of care? Journal of Affective Disorders. 2004;80:173–179. [PubMed: 15207930]
  • Van Schaik DJF, Klijn AFJ, van Hout HPJ, et al. Patients’ preferences in the treatment of depressive disorder in primary care. General Hospital Psychiatry. 2004;26:184–189. [PubMed: 15121346]
  • Van Straten A, Tiemens B, Hakkaart L, et al. Stepped care vs. matched care for mood and anxiety disorders: a randomized trial in routine practice. Acta Psychiatrica Scandinavica. 2006;113:468–476. [PubMed: 16677223]
  • Velazquez C, Carlson A, Stokes KA, et al. Relative safety of mirtazapine overdose. Veterinary and Human Toxicology. 2001;43:342–344. [PubMed: 11757992]
  • Vergouwen AC, Bakker A, Katon WJ, et al. Improving adherence to antidepressants: a systematic review of interventions. Journal of Clinical Psychiatry. 2003;64:1415–1420. [PubMed: 14728101]
  • Vize CM, Priest RG. Defeat Depression Campaign: attitudes to depression. Psychiatric Bulletin. 1993;17:573–574.
  • Von Korff M. Pain management in primary care: an individualized stepped-care approach, Psychosocial Factors in Pain. Gatchel RJ, Turk DC, editors. New York: Guilford Press; 1999. pp. 360–373.
  • Von Korff M, Goldberg D. Improving outcomes in depression: the whole process of care needs to be enhanced. British Medical Journal. 2001;323:948–949. [PMC free article: PMC1121496] [PubMed: 11679372]
  • Von Korff M, Gruman J, Schaefer J, et al. Collaborative management of chronic illness. Annals of Internal Medicine. 1997;127:1097–1102. [PubMed: 9412313]
  • Vothknecht S, Kho KH, van Schaick HW, et al. Effects of maintenance electroconvulsive therapy on cognitive functions. Journal of ECT. 2003;19:151–157. [PubMed: 12972985]
  • Wade AG, Toumi I, Hemels MEH. A pharmacological evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clinical Therapeutics. 2005;27:486–496. [PubMed: 15922821]
  • Wade AG, Toumi I, Hemels MEH. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Current Medical Research and Opinion. 2005;21:631–642. [PubMed: 15899113]
  • Wade AG, Fernàndez JL, François C, et al. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data. Pharmacoeconomics. 2008;26:969–981. [PubMed: 18850765]
  • Waddell G, Burton AK. Is Work Good for Your Health and Well-being? London: The Stationery Office; 2006.
  • Wagner EH. Managed care and chronic illness: health services research needs. Health Services Research. 1997;32:702–14. [PMC free article: PMC1070224] [PubMed: 9402910]
  • Wagner EH, Groves T. Care for chronic diseases. British Medical Journal. 2002;325:913–914. [PMC free article: PMC1124427] [PubMed: 12399321]
  • Wagner E, Austin B, von Korff M. Organizing care for patients with chronic illness. Milbank Quarterly. 1996;74:511–543. [PubMed: 8941260]
  • Wagner H, Bladt S. Pharmaceutical quality of hypericum extracts. Journal of Geriatric Psychiatry and Neurology. 1994;7(Suppl 1):S65–68. [PubMed: 7857515]
  • Walraven C, van Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. British Medical Journal. 2001;323:655–658. [PMC free article: PMC55923] [PubMed: 11566827]
  • Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. Journal of the American Medical Association. 2002;287:1840–1847. [PubMed: 11939870]
  • Wang Z-J, Lin S-M, Hu ML. Contents of hypericin and psuedohypericin in five commercial products of St John’s Wort (Hypericum perforatum) Journal of the Science of Food and Agriculture. 2004;84:395–397.
  • Waraich P, Goldner EM, Somers JM, et al. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Canadian Journal of Psychiatry. 2004;49:124–138. [PubMed: 15065747]
  • Watkins E, Scott J, Wingrove J, et al. Rumination-focused cognitive behaviour therapy for residual depression: a case series. Behaviour Research and Therapy. 2007;45:2144–2154. [PubMed: 17367751]
  • Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003;17:343–362. [PubMed: 12665392]
  • Weich S, Nazroo J, Sproston K, et al. Common mental disorders and ethnicity in England: the EMPIRIC study. Psychological Medicine. 2004;34:1543–1551. [PubMed: 15724884]
  • Weinmann S, Becker T, Koesters M. Re-evaluation of the efficacy and tolerability of venlafaxine V SSRIs: meta-analysis. Psychopharmacology. 2008;196:511–520. [PubMed: 17955213]
  • Weissman MM. Cognitive therapy and interpersonal psychotherapy: 30 years later. American Journal of Psychiatry. 2007;164:693–696. [PubMed: 17475722]
  • Weissman MM, Bland R, Joyce PR, et al. Sex differences in rates of depression: cross-national perspectives. Journal of Affective Disorders. 1993;29:77–84. [PubMed: 8300980]
  • Weissman MM, Markowitz JC, Klerman GL. Comprehensive Guide to Interpersonal Psychotherapy. New York: Basic Books; 2000.
  • Westen D, Novotny CM, Thompson-Brenner H. The empirical status of empirically supported psychotherapies: assumptions, findings, and reporting in controlled clinical trials. Psychological Bulletin. 2004;130:631–663. [PubMed: 15250817]
  • Westrin A, Lam RW. Seasonal affective disorder: a clinical update. Annals of Clinical Psychiatry. 2007;19:239–246. [PubMed: 18058281]
  • Whitfield G, Williams C, Shapiro D. Assessing the take up and acceptability of a self-help room used by patients awaiting their initial outpatient appointment. Behavioral and Cognitive Psychotherapy. 2001;29:333–343.
  • Whittington C, Cape J, Buszewicz M, et al. Comparison of collaborative care for depression and anxiety in primary care with traditional general practice attachments: a meta-analysis and meta-regression. Manuscript in preparation. 2009
  • WHO. The ICD–10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: WHO; 1992.
  • WHO. World Health Report 2001: Mental Health: New Understanding, New Hope. Geneva, Switzerland: WHO; 2001.
  • WHO. The World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva, Switzerland: WHO; 2002. [PubMed: 14741909]
  • Whooley MA, Avins AL, Miranda J, et al. Case-finding instruments for depression. Two questions are as good as many. Journal of General Internal Medicine. 1997;12:439–445. [PMC free article: PMC1497134] [PubMed: 9229283]
  • Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM. 2003;96:369–374. [PubMed: 12702786]
  • Wiersma D, Kluiter H, Nienhuis F, et al. Day-treatment with Community Care as an Alternative to Standard Hospitalisation: An Experiment in the Netherlands. A Preliminary Communication. Groningen, the Netherlands: Department of Social Psychiatry, University of Groningen; 1989.
  • Wijkstra J, Nolen WA. Successful maintenance electroconvulsive therapy for more than seven years. Journal of ECT. 2005;21:171–173. [PubMed: 16127307]
  • Wilfley DE, MacKenzie KR, Welch RR, et al. Interpersonal Psychotherapy for Group. New York: Basic Books; 2000.
  • Williams JBW, Link MJ, Rosenthal NE, et al. Structured Interview Guide for the Hamilton Depression Rating Scale: Seasonal Affective Disorders Version (SIGH-SAD). New York: New York Psychiatric Institute; 1988.
  • Williams JM, Russell I, Russell D. Mindfulness-based cognitive therapy: further issues in current evidence and future research. Journal of Consulting and Clinical Psychology. 2008;76:524–529. [PMC free article: PMC2834575] [PubMed: 18540746]
  • Williams JW Jr, Kerber CA, Mulrow CD, et al. Depressive disorders in primary care: prevalence, functional disability, and identification. Journal of General Internal Medicine. 1995;10:7–12. [PubMed: 7699487]
  • Williams MD, Rummans T, Sampson S, et al. Outcome of electroconvulsive therapy by race in the Consortium for Research on Electroconvulsive Therapy multisite study. Journal of ECT. 2008;24:117–121. [PMC free article: PMC3926099] [PubMed: 18580553]
  • Williams R, Hunt K. Psychological distress among British South Asians: the contribution of stressful situations and subcultural differences in the West of Scotland Twenty-07 Study. Psychological Medicine. 1997;24:113–119. [PubMed: 9300521]
  • Wilson K, Mottram P, Sivanranthan A, et al. Antidepressant versus placebo for depressed elderly (Cochrane Review), Cochrane Library. 2. Oxford: Update Software; 2001. [PubMed: 11405969]
  • Wilson M, MacCarthy B. GP consultation as a factor in the low rate of mental health service use by Asians. Psychological Medicine. 1994;27:1173–1181. [PubMed: 8208876]
  • Winokur G, Coryell W, Keller M. A prospective study of patients with bipolar and unipolar affective disorder. Archives of General Psychiatry. 1993;50:457–465. [PubMed: 8498880]
  • Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D Report. American Journal of Psychiatry. 2009;166:599–607. [PubMed: 19339358]
  • Wittchen HU, Hofler M, Meister W. Prevalence and recognition of depressive syndromes in German primary care settings: poorly recognized and treated? International Clinical Psychopharmacology. 2001;16:121–135. [PubMed: 11354234]
  • Wittchen HU, Schuster P, Lieb R. Comorbidity and mixed anxiety–depressive disorder: clinical curiosity or pathophysiological need? Human Psychopharmacology. 2001;16(Suppl 1):S21–30. [PubMed: 12404532]
  • Wolberg LR. Short-term Psychotherapy. New York: Grune & Stratton; 1967.
  • Wolpe J. Neurotic depression: experimental analogue, clinical syndromes and treatment. American Journal of Psychotherapy. 1971;25:362–368. [PubMed: 5568116]
  • Wolpe J. The experimental model and treatment of neurotic depression. Behaviour Research and Therapy. 1979;17:555–565. [PubMed: 526246]
  • World Bank. World Development Report: Investing in Health Research Development. Geneva, Switzerland: World Bank; 1993.
  • Wyeth Pharmaceuticals. Efexor XL. Summary of Product Characteristics. Maidenhead: Wyeth; 2008. Available at: http://www​.medicines​.org.uk/EMC/history/2210/SPC/Efexor+XL.
  • Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. Journal of Psychiatric Research. 1983;17:37–49. [PubMed: 7183759]
  • Zajecka J, Fawcett J, Amsterdam J, et al. Safety of abrupt discontinuation of fluoxetine: a randomised, placebo-controlled study. Journal of Clinical Psychopharmacology. 1998;18:193–197. [PubMed: 9617977]
  • Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis I comorbidity of borderline personality disorder. The American Journal of Psychiatry. 1998;155:1733–1739. [PubMed: 9842784]
  • Zhang ZJ, Tan QR, Tong Y, et al. The effectiveness of carbamazepine in unipolar depression: a double blind, randomised, placebo controlled study. Journal of Affective Disorders. 2008;109:91–97. [PubMed: 18093662]
  • Zigmond AS, Snaith RD. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica. 1983;67:361–370. [PubMed: 6880820]
  • Zimmerman M, Thongy T. How often do SSRIs and other new-generation antidepressants lose their effect during continuation treatment? Evidence suggesting the rate of true tachyphylaxis during continuation treatment is low. Journal of Clinical Psychiatry. 2007;68:1271–1276. [PubMed: 17854252]
  • Zimmerman M, Chelminski I, McGlinchey JB, et al. Diagnosing major depressive disorder X: can the utility of the DSM–IV symptom criteria be improved? The Journal of Nervous and Mental Disease. 2006;194:893–897. [PubMed: 17164626]
  • Zimmerman M, McGlinchey JB, Posternak MA, et al. Remission in depressed outpatients: more than just symptom resolution? Journal of Psychiatric Research. 2008;42:797–801. [PubMed: 17986389]
  • Zisselman MH, Rosenquist PB, Curlik SM. Long-term weekly continuation electroconvulsive therapy: a case series. Journal of ECT. 2007;23:274–277. [PubMed: 18090702]
  • Zung WWK. A self-rating depression scale. Archives of General Psychiatry. 1965;12:63–70. [PubMed: 14221692]

Footnotes

232

Where more than one paper has been published from a study, the guideline adopts the convention of the Cochrane Collaboration so that the study is referred to by the author and date of the original study regardless of whether data have been extracted from subsequent papers. The additional papers are listed under the first paper in the appendices.

233

This is also the reference for Benkert et al., 1997 (2nd cf).

Copyright © The British Psychological Society & The Royal College of Psychiatrists, 2010.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

Bookshelf ID: NBK63749

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (6.5M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...